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ABSTRACT OF DISSERTATION 
RHODOCOCCUS EQUI IN THE FOAL – IMPROVING DIAGNOSTIC AND PREVENTION 
MEASURES 
Although Rhodococcus equi (R. equi), previously known as Corynebacterium equi, was 
first isolated from pneumonic foals almost a century ago, it remains the most common cause of 
subacute or chronic granulomatous bronchopneumonia in foals. While the majority of foals 
exposed to R. equi develop a protective immune response (regressors), others exhibit a unique 
susceptibility to infection (progressors). The determinants for either outcome are not completely 
understood. Therefore, current diagnostic and preventive measures are suboptimal and require 
betterment. In light of this current need, we hypothesized that immunoglobulin G subisotype T 
[IgG(T)] against the virulence-associated protein A (VapA) of R. equi, and whole blood cytokine 
expression profile of foals predict the outcome of infection and can be used as diagnostic markers 
of clinical disease. Further, we hypothesized that the use of R. equi hyperimmune plasma (HIP) 
decreases severity of disease in naturally infected foals, playing an important role in disease 
prevention in the field. Lastly, we hypothesized that specific anti-Rhodococcus equi pili antibodies 
passively acquired by foals via colostrum after immunization of pregnant mares with a 
Rhodococcus equi pili-based candidate vaccine will confer protection against induced disease, and 
therefore have an immediate impact on R. equi pneumonia prophylaxis.  
The objectives of this study were: (1) to describe the humoral immune response of 
progressor and regressor foals to R. equi following experimental challenge and natural infection, 
(2) to compare the cytokine and cell-marker expression profile in whole blood of progressor and 
regressor foals after challenge, (3) to evaluate the Vap-A specific IgG profile of a commercially 
available HIP product and its value as a prophylactic tool on an endemic farm, and (4) to evaluate 
the efficacy of a vaccine based on the Rhodococcus equi pili (Rpl).  
Although the IgG(T) response of progressor foals after challenge or following natural 
infection tended to be more pronounced than that observed in regressor foals, its performance as a 
diagnostic test for predicting disease outcome was poor. Likewise, whole blood cell-marker and 
cytokine expression profiles of progressor and regressor foals were not significantly different, 
undermining its reliability as a diagnostic tool. Evaluation of the association of HIP VapA specific 
IgG profile and rhodococcal disease outcome in the field resulted in the conclusion that progressor 
foals received significantly less VapA specific IgG, suggesting that HIP may have provided some 
protection to regressor foals. Although HIP appeared to have provided some protection against 
clinical pneumonia, Rpl maternally-derived IgG failed to confer any advantage to foals born from 
vaccinated mares. The Rpl candidate vaccine failed to confer protection to foals after challenge, 
and did not decrease disease severity in comparison to a control group.  
In summary, the results of this study do not support the use of VapA specific IgG(T) or 
whole blood cytokine expression profile as predictors of disease outcome. Further, our results 
suggest a positive effect of HIP on disease outcome. Lastly, the presence of systemic and local Rpl 
antibodies was not protective in foals.  
KEY WORDS: Rhodococcus equi, foal, VapA, IgG(T), hyperimmune plasma, vaccine. 
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CHAPTER 1 
LITERATURE REVIEW AND RESEARCH HYPOTHESES 
 
Introduction 
Rhodococcus equi is considered one of the most important pathogens of early life in horses 
worldwide 1. In infected foals, a wide range of respiratory disease can be observed varying from 
subclinical lung lesions to life-threatening suppurative bronchopneumonia that may develop within 
the first months of life 1,2. Endemically infected farms experience morbidity of 70% or greater, and 
case fatalities range from 13% to 40% for R. equi pneumonia 3–6. This disease has a major negative 
financial impact in the equine industry due to the ubiquitous pathogen distribution, high cumulative 
disease incidence on affected farms, and costly preventive and treatment measures. Although R. 
equi is most often recognized as an etiologic agent of bronchopneumonia in foals, other body 
systems can be infected, as well as immunocompromised humans and other animal species1,7. 
R. equi belongs to an extended genus of ubiquitous Actinobacteria with more than 35 
recognized species, among which R. equi remains the species with the most pathogenic potential 
for humans and animals. Rhodococcus spp. are obligatory aerobic, non-motile, non-spore-forming 
gram-positive coccobacilli. They are part of the phylogenetic group described as mycolata, 
characterized by a unique cell envelope that consists of mycolic acids covalently linked to the 
arabinogalactan-peptidoglycan layer of the cell wall8. This thick hydrophobic outer membrane-like 
sheath protects the actinomycetes from environmental and host-derived assaults 9. R. equi is 
primarily a soil saprophyte, where it uses herbivore manure as a growth substrate, explaining its 
widespread distribution in horse farms where the infection is primarily contracted by inhalation of  
aerosolized R. equi in dust10.  
R. equi is a facultative intracellular pathogen, which parasitizes macrophages causing 
granulomatous inflammation1. In affected foals, alveolar macrophages are the primary survival and 
replication niche for the inhaled R. equi 11. Macrophage uptake is mediated either via complement 
receptor 3 (CR-3 or Mac-1) or mannose receptor, which recognizes residues of the bacterial cell 
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envelope12,13. Entry through these receptors bypasses the antibody-mediated Fcγ receptor pathway 
and may play a major role in promoting macrophage colonization by R. equi, while uptake of 
opsonized R. equi with specific antibodies against unkown surface antigens is likely to result in 
intracellular killing 14. Overwhelming intracellular replication of R. equi results in cell necrosis, 
release of a multitude of pro-inflammatory signals, culminating in tissue abscessation and 
destruction15. The ability to survive intracellularly in macrophages is conferred to Rhodococcus by 
a family of plasmid encoded determinants, known as virulence associated proteins (Vap) 16. 
Virulence associated proteins are small, secreted proteins that weigh 17-20 kDa and are 164-202 
amino acids long. Gene deletion and complementation studies have shown that VapA, one of the 
nine Vap encoded in the bacterial plasmid, is the primary R. equi virulence determinant17. Virulent 
R. equi are able to modify the phagocytic vacuole of host macrophages to prevent acidification and 
subsequent fusion with lysosomes18, by molecular mechanisms yet to be determined. A second key 
R. equi virulence determinant discovered during the analysis of the R. equi genome is a 
chromosomal horizontally acquired island that encodes for cytoadhesive Flp type IVb subfamily 
pili 19. The R. equi pili (Rpl) form long, rigid appendages, typically 2-5 per bacterial cell19 that 
mediate attachment to epithelial cells and macrophages and are essential for lung colonization in 
live mice 20. 
Epidemiological evidence from field and challenge studies indicates that foals are most 
susceptible to rhodococcal infections shortly after birth 21–24, when exposure to ubiquitous R. equi 
is likely to occur. While the majority of foals infected with R. equi shows spontaneous resolution 
of lung lesions, others exhibit a unique susceptibility to infection. The determinants for either 
outcome are not completely understood.  
 
Innate immunity of the healthy foal 
The innate immune system plays a critical role in protecting neonates against infections 
since antigen-specific immune responses require previous exposure and time for development. A 
critical determinant for an evolutionary conserved immature innate immune response in young 
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mammals is the high antigenic pressure that follows birth, posed not only by a wide variety of 
pathogens, but also by commensals, as well as harmless environmental and food antigens. This 
high load of novel antigens requires well-established immune regulatory mechanisms in order to 
allow concomitant protective responses and the development of immune self-recognition and 
tolerance. These are crucial mechanisms necessary for effective control of inflammatory reactions 
and adequate cell growth and proliferation early in life25. Therefore, it is no surprise that the finely 
regulated immune system of the foal differs from that of the adult horse in the way it responds to 
immune challenges. The overall competency of the foal’s innate immune system has been 
addressed through investigations of phagocyte function and expression of cytokines, activation 
markers, and cell receptors.  
  
Phagocyte function 
As the most abundant white blood cell in the peripheral blood, neutrophils are critical 
effectors cells of innate immunity26. In healthy foals up to 3 weeks of age, neutrophils have 
impaired in vitro yeast phagocytic activity in the presence of autologous serum. However, in the 
presence of pooled serum from adult horses or specific IgG, the same neutrophils are able to 
phagocytose yeast cells. This finding suggests that neutrophils are competent phagocytes at birth, 
and that the cause for early decreased phagocytosis is associated with the neonatal serum27. The 
fact that serum IgG concentrations remain low in foals during the first few months of life, implies 
that other opsonic factors, such as complement, may be of greater importance in neutrophil 
phagocytosis28. Indeed, it has been shown that the inhibition of complement-mediated opsonisation 
by heat inactivation reduces the phagocytic capacity of neutrophils29.  
Studies evaluating early neutrophil killing capacity in foals have shown contradictory 
results. When chemiluminescence was used to quantify oxidative burst, Demmers et al. found that 
the killing capacity of neutrophils was significantly lower following birth but, from 3 months 
onwards, values were equal to or exceeded that of mature horses27. However, a previous study using 
a similar experimental design showed no significant changes in chemiluminescence response in 
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foals from birth to 6 months of age14. When flow cytometry was used to access oxidative burst 
activity in foal neutrophils, no age-dependent changes were identified30. The reasons for these 
conflicting results are not clear.  
Peripheral blood phagocytic activity of leukocytes in the healthy foal has been evaluated 
via a simultaneous phagocytosis and oxidative burst activity assay31. No age-dependent maturation 
of phagocyte function was identified, and phagocytosis was optimized in the presence of 
opsonizing serum. Therefore, as shown with neutrophils, these cells were also deemed competent 
at birth.  
Bronchoalveolar lavages obtained from foals of 1 to 21 days of age have shown a numerical 
deficiency in alveolar macrophages up to 2 weeks of age, when compared to older horses (2-3 years 
of age)32. Alveolar macrophages obtained from 2-3-day old foals also demonstrated significant 
impaired chemotactic function. These numerical and chemotactic deficiencies of the neonatal foal 
have been suggested to play a role in the foal’s susceptibility to respiratory disease. 
 
Expression of cytokines, activation markers, and cell receptors 
Non-phagocytic mechanisms may also play a role in protection against intracellular 
pathogens. The induction of protective resistance to infectious diseases is influenced by the pattern 
and magnitude of cytokine gene expression33. In other species, neutrophils produce a variety of 
cytokines and chemokines that modulate the immune response by recruiting and activating other 
effector cells of the immune system34.  Neutrophil expression of interleukine (IL) 6 and IL-8 in 
healthy newborn foals (< 24 hours of birth) is significantly greater than expression at 2-, 4-, and 8-
weeks of age35. The role of IL-6 in infection is controversial, but the majority of the evidence 
suggests it is required for protection against a number of bacterial infections36–39. IL-8 is a potent 
chemoattractant of neutrophils, monocytes and T-cells, and has been shown to enhance killing of 
Mycobacterium tuberculosis by neutrophils40–42. Therefore, it is possible that in newborn foals 
enhanced expression of IL-6 and IL-8 is needed for pathogen protection. 
Most recently, it has been demonstrated that cytosine-phosphate guanine 
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oligodeoxynucleotide (CpG-ODNs) can activate cytokine expression and reactive oxygen species 
(ROS) production by neutrophils in foals older than 2 weeks of age43. Similar studies using foals 
younger than 2 weeks revealed that in vitro stimulation with CpG-ODN also significantly increased 
pro-inflammatory cytokine gene expression and degranulation of neutrophils collected from foals 
as young as 1 day old44. When CpG-ODN was subsequently administered intramuscularly to live 
foals at 1 and 7 days of age, there was a significant increase in the IFN-γ mRNA expression by the 
foal’s neutrophils, suggesting that the administration of this compound may improve the foal’s 
early immune responses45.    
Cytokines released from innate immune cells play key roles in the regulation of the immune 
response33. Recent studies in neonatal humans, mice and other species have shown that neonates 
are deficient in the production of IFN-γ and IL-646–48. The impaired production of these pro-
inflammatory cytokines has been proposed as the basis of the deficiency in neonatal innate 
immunity, which contributes to impaired neonatal host defenses in newborns26,49. Based on studies 
that evaluated PBMCs, foals have also being suggested as being IFN-γ deficient at birth50–52, and 
this immunodeficiency has been assumed to contribute to the vulnerability of neonatal foals to a 
wide variety of pathogens51,53.  
IL-1 plays an important role in nonspecific immunological defense. It enhances activity of 
natural killer cells, promotes maturation and proliferation of B cells, chemotactically attracts 
neutrophils and macrophages, and initiates synthesis of acute phase proteins by the liver, along 
with IL-6 and TNF-α 54,55. While its innate functions are crucial to the immune system, the ability 
of IL-1 to evoke protective immunity is limited. IL-1α and IL-1β deficient mice have shown no 
unique susceptibility to common pathogens56. In fact, instances of IL-1 over-expression have lead 
to health complications. Sepsis, for example, is a common ailment of neonatal foals. During sepsis 
in foals, IL-1 is released early as part of an inflammatory response, resulting in tissue damage57. 
TGF-β has potent immunomodulating properties that can be contradictory depending on the 
cytokine environment and surrounding cell type58. Although TGF-β is chemotactic for neutrophils 
and monocytes, it also limits inflammatory responses and promotes wound healing59. 
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Toll-like receptors (TLRs) are key components of the innate immune system, because they 
recognize conserved structural pathogen-associated molecular patterns (PAMPs) and initiate 
signaling cascades upon ligand biding to activate immune cells. TLR-8 recognizes single-stranded 
RNAs and plays a role in the innate anti-viral immune response60. Foal neutrophils of all ages 
express TLR-8 mRNA constitutively, and stimulation of the TLR-8 signaling pathway induces 
mRNA expression of inflammatory cytokines IL-6 and IL-8 in neutrophils from foals at 1 and 14 
days of age61. TLR-9 detects bacterial DNA, which is distinguished by unmethylated CpG motifs, 
and its signaling promotes functional activity of neutrophils against intracellular pathogens 60. 
Neutrophils from newborns and two-month-old foals express levels of TLR-9 mRNA comparable 
to those of adult horse neutrophils, and stimulation of foal and adult neutrophils with CpG induces 
IFN-γ, IL-8, and IL-12 mRNA expression, while TNF-α mRNA is downregulated43. Foal dendritic 
cells and macrophages express TLR-9 mRNA comparable to adult horse cells, however, CpG-ODN 
treatment did not induce specific maturation and cytokine expression in foal macrophages and 
dendritic cells62. Also, despite high levels of TLR expression, the in vitro activation of TLR-2 had 
no immunomodulatory effect over TLR-4-mediated inflammatory response in peripheral blood 
mononuclear cells (PBMCs) from neonatal foals, contrary to what has been reported in several in 
vivo studies in experimental animals63–65. The lower functional response observed after TLR 
activation in neonatal foals has been proposed as a strategy to limit the immune responses to the 
bacterial colonization of epithelial surfaces during the early period of life63. 
  
Adaptive immunity of the healthy foal 
Cell-mediated immunity 
Although much of the lymphoid tissue develops during gestation, the foal’s adaptive 
immune system is naive at birth, thus lacking pathogen-specific B and T effector cells, as well as 
B and T memory cells and preformed antibodies. Consequently, they are highly susceptible to 
intestinal and respiratory pathogens, including rotavirus, R. equi and others, many of which rarely 
occur in adults and only as opportunistic pathogens66.  
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The exposure to an abundant and diverse population of pathogens in early life induces a 
massive expansion of antigen-specific lymphocyte populations, reflected by a 2-3 times increase in 
the number of circulating lymphocytes and an increase in mass of secondary lymphoid tissues30.  
In healthy foals, absolute circulating CD4+ and CD8+ T lymphocytes and B cells increase linearly 
up to 3 months of age, plateauing at a number greater than that of adult horses for a few months, 
before dropping toward adult horse reference values67. Peripheral leukocyte function has been 
assessed in the foal. While an age-dependent peripheral blood leukocyte proliferation in response 
to mitogen stimulation (Concanavalin A) was described during the first few weeks of life, general 
immune function (lymphokine activated killing activity, opsonized phagocytosis, and oxidative 
burst activity) of newborns was similar to the adult horse30. Neonatal antigen presenting cells 
(APCs) also undergo age-dependent changes over the first few months of life. Foal macrophages 
and dendritic cells express relatively lower levels of major histocompatibility complex (MHC) class 
II antigen in comparison to adult horses, suggesting a limited capacity to present processed 
extracellular antigens to T cells before exposure to environmental stimulation causes increased 
expression of immunoregulatory molecules62,68. In addition, fewer numbers of mature dendritic 
cells (CD14-CD1b+CD86+) are detected in foals younger than 3 months of age when compared to 
adult horses69.  
Although the majority of the peripheral lymphoid organs develop throughout fetal life, only 
an insignificant number of T cells can be detected in the equine fetal lung, and the bronchus-
associated lymphoid tissue (BALT) will only be detected in 12-week or older foals60,68.  
Consequently, leukocyte populations in the bronchoalveolar lavage fluid (BALF) increase with 
age, with the numbers in foals aged 1 week being only 10% of those in adults68. Adult-like CD4+ 
and CD8+ BALF T cell concentrations are reached by 3 and 10 weeks of age, respectivelly70. Very 
few B lymphocytes or plasma cells are identified in the BALF before 8 weeks of life30. As observed 
with peripheral blood lymphocytes, lymphocytes from the BALF collected from foals younger than 
6 weeks of age express lower MHC class 2 molecules than in adult horses70. Few alveolar 
macrophages are recovered in BALF up to two weeks of life but, by the third week, greater than 
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70% of the recovered cells are alveolar macrophages. While healthy foals have significantly higher 
percentages of macrophages in the BALF at one month compared with 12 months of age, the 
lymphocyte percentages are significantly higher at 12 months of age compared with 1 week of 
life69.  
As for T cell immunity, T helper (Th) cell subsets play major roles in regulating adaptive 
immunity. Studies in mice have shown that a Th1 response, characterized by IFN-γ production, is 
sufficient to effectively promote pulmonary clearance of R. equi whereas a Th-2 response, 
characterized by IL-4 production, is detrimental72,73. Whether a CD4+ T helper lymphocyte 
differentiates into its Th1 or Th2 subset depends largely on the cytokine environment58. IL-12, for 
example, is produced by activated macrophages and dendritic cells and strongly stimulates the 
naïve T helper cell to differentiate into Th1 cells74,75. Once T cells have differentiated into a Th1 or 
Th2 subset, the immune response tends to persist in that direction because Th1 cells produce 
cytokines that inhibit Th2 cell development and vice versa. Both human and murine neonatal T 
cells are impaired in producing Th1 cytokines IL-2 and IFN-γ under relatively neutral conditions76. 
Thus, evidence from other species indicates that it is important to characterize cytokine expression 
and to evaluate cytokine expression as a function of age in foals. Characterizing cytokine 
expression and examining quantitative changes could help define the role of cytokines in the 
susceptibility of foals to infectious diseases.  
Currently, Th-cell responses in neonatal and young foals are controversial. Several studies 
have indicated a weak Th1 immune response in healthy newborn and young foals. For example, 
neonatal PBMCs have been shown to express less IFN-γ, transforming growth factor (TGF)-β and 
IL-1α mRNA transcripts in comparison with cells from adult horses, but their expression 
significantly increased with age reaching adult levels within the first year of life50,51. The neonate’s 
inability to express the IFN-γ gene and produce IFN-γ protein has also been reported in cells from 
bronchoalveolar lavage (BAL) obtained from foals at 1 month of age51. These findings suggest that 
a maturational development of a Th1 response occurs during the early life, and that the weaker Th1 
response occurs during the neonatal period, which may contribute to the foal’s susceptibility to 
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intracellular pathogens. However, one study has shown that young foals can produce small amounts 
of IFN-γ via Th1 and CD8+ cytotoxic T cells and that regulatory IL-10 production by T cells is 
developmentally mature in foals77.  
 
Humoral immunity 
Although immunoglobulin production in foals begins in utero, serum IgM and IgG levels 
are low and not protective at birth. Regardless of colostrum intake, it is only by 2-3 months of life 
that significant concentrations of endogenous IgM and IgG in the serum are observed67. If passive 
transfer successfully occurs, the total serum IgG and IgM reach the lowest concentrations when the 
foal is 1-3 months old, due to the decay of colostrum-derived antibodies67,78. One important aspect 
of this dynamic phase of circulating colostrum-derived antibodies and endogenously-produced 
antibodies is the need for humoral protection, not only at birth but also in the initial few months of 
life. Therefore, what is considered to be standard adequate transfer of antibodies through colostrum 
at birth (e.g., at least 800 mg/dL), questionably, in theory, provides humoral protection in the first 
3 months of life, when considering an IgG half-life of approximately 30 days, and a minimal 
circulating level of 500 mg/dL. Nonetheless, levels greater than 1000-1200 mg/dL would provide 
even greater protection in the first few months of life. Indeed, adequate transfer of 
immunoglobulins occurs naturally at levels much higher than 800 mg/dL, and varies among 
breeds30,60.  
Only recently the full complement of the horse Ig heavy chain constant region genes has 
been described, increasing the known number of IgG subclasses to seven79. Earlier studies 
described five equine IgG subclasses named IgGa, IgGb, IgGc, IgG(T), and IgG(B). Following the 
identification of the seven horse heavy chain constant region genes, the IgG subclasses have been 
reassigned as IgG1 to IgG780. Of the originally described IgG subclasses, IgGa corresponds to 
IgG1, IgGb to IgG4 and IgG7, IgGc to IgG6, and IgG(T) to both IgG3 and IgG579. In order to 
remain faithful to the findings of the referenced authors, the IgG subclass nomenclature here will 
adhere to those used in the original publication. 
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Several studies evaluating humoral immunity of foals have focused on IgG antibody 
because of its important opsonic activity81,82. Analysis of the different effector function capabilities 
of the seven equine IgG subclasses revealed that IgG1, IgG3, IgG4, IgG5 and IgG7, but not IgG2 
and IgG6, elicit a strong respiratory burst from equine peripheral blood leukocytes. IgG1, IgG3, 
IgG4 and IgG7, but not IgG2, IgG5 and IgG6, bind complement C1q and activate complement via 
the classical pathway 83. 
IgGb is the most abundant IgG subclass in adult horse serum (followed by IgG(T) and 
IgGa) and colostrum (followed by IgGa and IgG(T)), yet its endogenous synthesis could not be 
detected in healthy foals until 63 days after birth78. In contrast, IgGa, IgG(T) and IgA can be 
detected in foal serum within the first 5-8 weeks of life. IgGa increases by 2-3 months to 
concentrations 3-fold higher in foal than in adult serum. IgGb concentration in foal serum was 
lower than that of IgGa or IgG7 between 12 weeks and 8 months and had not attained adult 
concentrations by one year of age84. Since the effector function of these IgG subclasses overlap 
widely, the delay in IgGb production may be functionally compensated by the higher circulating 
IgGa and adult-like IgG(T). It should be emphasized that endogenous antibody production in foals 
was measured in the presence of residual maternal antibodies and therefore, the true onset of 
antibody production in foals may have been underestimated. Foal Ig production starts before birth 
for IgGa, shortly after birth for IgG(T) and IgA, and likely begins at around 5 weeks of age for 
IgGb25. 
Concentrations of immunoglobulins have been determined in nose wash samples obtained 
from foals immediately after parturition and on days 1, 7, 14, 28, 42 and 63 of life. The major 
isotype reported in nasal secretions of foals older than 28 days was IgA, while IgGa and IgGb were 
the predominant immunoglobulins in foals younger than 14 days of age. The combination of few 
lymphocytes in the lungs with the lack of IgA in the upper airway of young foals, has been 
suggested as a predisposing factor to respiratory disease85.  
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Foal’s innate immune response to R. equi  
The importance of neutrophils in controlling early R. equi tissue infection and decreasing 
disease severity in mice was demonstrated by Martens et al., 200586.  Anti-neutrophil monoclonal 
antibody-induced neutrophil deficiency during the first week after experimental infection with R. 
equi resulted in more severe disease and significantly increased bacterial tissue concentrations. In 
the foal, the protective role of neutrophils against R. equi has been controversial. The in vitro 
bactericidal capacity of neutrophils against opsonized R. equi was found to be statistically similar 
among neonates, 1-month old foals, and adult horses87. However, some neonatal foals (15%) 
showed a substantially reduced capacity to kill R. equi, which was suggested as a potential 
important factor in the pathogenesis of R. equi infections. Further, relatively lower circulating 
neutrophil concentrations in foals at 2 and 4 weeks of age were associated with a significant higher 
likelihood of subsequent development of R. equi pneumonia compared to foals with higher 
concentrations88. On the other hand, several authors have suggested that foal neutrophils are 
functional cells and are not a contributing factor in the pathogenesis of R. equi pneumonia. Yager 
et al. have described an intact in vitro bactericidal capacity of neutrophils in neonatal foals89. Age-
related changes in basal and R. equi-stimulated cytokine gene expression by foal neutrophils have 
shown that they are able to increase mRNA expression of many pro-inflammatory cytokines, 
including IFN-γ, in response to in vitro stimulation with virulent R. equi, and the magnitude of this 
increase in expression is influenced by age starting at birth35,43.  
Dendritic cells (DCs) are vitally important in the initial stages of infection for the 
production of a successful and efficient immune response. Maturational differences have been 
found between DCs of foals and adults, including a reduced ability of DCs of foals to produce TNF-
α in response to LPS stimulation69.  While R. equi challenged foal DCs produce equivalent amounts 
of IL-12, a cytokine which promotes a Th1 response and IFN-γ production, they failed to upregulate 
MHCII expression when compared to adult DCs90,. This could lead to impaired ability to interact 
with and stimulate naïve T-cells. Differential expression of additional 19 immunologically relevant 
genes has been identified in foal and adult monocyte-derived DCs in response to R. equi infection, 
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providing promising targets for further research into the host response to R. equi, and the 
susceptibility of foals to this disease91. 
Given the structural similarity between Mycobacterium tuberculosis and R. equi, the role 
of MHC-unrestricted cytotoxic T lymphocytes, and the expression of CD-1 molecules in antigen-
presenting cells of foals and adult horses has been investigated92. Protective immune responses to 
M. tuberculosis involve classical major histocompatibility complex MHC-restricted T cells that 
recognize peptide antigen, as well as MHC-independent T cells that recognize mycobacterial lipid 
antigen presented by CD-1 molecules. The CD-1b isoform is evolutionarily conserved and is 
present on equine monocyte-derived macrophages. However, both CD-1b and MHCII expression 
are significantly lower in foal monocyte-derived macrophages compared with adult horses, which 
could partially explain the unique susceptibility of foals to R. equi infection. Most interestingly, 
infection of monocyte-derived macrophages induced down-regulation of CD-1b on the cell surface, 
which may represent a novel mechanism by R. equi to avoid detection and killing of infected cells 
by the immune system. 
Whether macrophage age and lineage affect intracellular survival of R. equi and modulate 
the production of cytokines after infection has been investigated in vitro93. Intracellular survival of 
virulent R. equi in both monocyte-derived and bronchoalveolar macrophages from foals showed 
significantly greater bacterial replication in 3-month old foals than in 3-day old foals, 2-week old 
foals, 1-month old foals, and adult horses. Regardless of age, intracellular replication of R. equi 
was significantly greater in bronchoalveolar than in monocyte-derived macrophages. Expression 
of IL-4 mRNA was significantly higher in monocyte-derived macrophages whereas expression of 
IL-6, IL-18 and TNF-α was significantly higher in bronchoalveolar macrophages. It is possible that 
the decreased killing capacity of macrophages in foals of 3 months of age may play a role in the 
timing of disease presentation. Furthermore, preferential intracellular survival of R. equi in 
bronchoalveolar macrophages may explain the pulmonary tropism of the pathogen. 
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Foal’s adaptive immune response to R. equi  
Cell-mediated immunity  
 Since immunocompetent adult horses are immune to rhodococcal pneumonia, a better 
understanding of the mechanisms of immune clearance in these animals could help define the 
requirements for a protective immune response in foals.  Upon intrabronchial challenge of adult 
horses with virulent R. equi, and subsequent follow up of local and peripheral blood responses, 
clearance of bacteria was associated with increased mononuclear cells (primarily lymphocytes) in 
the bronchoalveolar lavage fluid, and inversion of the normal macrophage:lymphocyte ratio94. 
Furthermore, flow cytometric analysis of the bronchoalveolar lavage fluid demonstrated that 
clearance correlated with significant increases in pulmonary T-lymphocytes, including both CD4+ 
and CD8+ cells. These results are compatible with previous work performed in mice, which also 
showed that both CD4+ and CD8+ T-cells played a role in clearance of R. equi95. When adult horses 
were challenged with either virulent or avirulent R. equi (plasmid-cured derivative), clearance of 
the virulent strain was associated with increased numbers of pulmonary CD4+ and CD8+ 
lymphocytes producing IFN-γ, while the plasmid-cured strain was cleared in horses without a 
significant increase in IFN-γ producing T lymphocytes in the bronchoalveolar lavage fluid96. 
Interestingly, there was no change in the IFN-γ-positive cells in the peripheral blood of horses that 
cleared virulent R. equi from the lung, suggesting that a local, type 1 recall response was sufficient 
to confer protection. Furthermore, the cytotoxic T lymphocytes (CTLs) via non-classical MHC 
molecules (CD-1b), have been demonstrated to contribute to the immune control of R. equi in adult 
horses 97.  
 In contrast to adult horses, infection of foals with virulent R. equi resulted in decreased 
local IFN-γ mRNA expression in lung CD4+ cells98. The inability of foals to respond to infection 
with adult-like T cell responses and with comparable IFN-γ production has been deemed 
responsible for the increased susceptibility of foals to intracellular pathogens such as R. 
equi51,52,99,100. On the other hand, foal innate immune cells, such as monocyte-derived dendritic 
cells, respond to virulent R. equi infection with increased IL-12 mRNA expression compared to 
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cells from adult horses.90 Foal PBMCs also showed a clear upregulation of IFN-γ mRNA, decreased 
IL-4 gene expression and greater IFN-γ/IL-4 transcript ratios in response to R. equi infection 
compared with adult horses101. This showed that Th-cells of young foals can generally produce 
IFN-γ but have a substantially reduced capacity to develop into IL-4 producing Th2-cells. 
 The effect of inoculum size on cell-mediated immune responses of foals challenged with 
R. equi has been studied in foals challenged intrabronchially between 7-12 days of age, with either 
a 106 or 108 cfu inoculum. Proliferative response assay as well as quantification of mRNA cytokine 
expression (IL-2, IL-4, IL-10, and IFN-γ) after in vitro stimulation with soluble R. equi antigen 
were performed on mononuclear cells harvested from bronchial lymph nodes 15 days after 
infection. Concanavalin A and C. pseudotuberculosis were positive and negative controls. 
Proliferative responses to positive and negative controls and R. equi antigen, as well as expression 
of mRNA for IL-2, IL-4, IL-10, and IFN-γ were not significantly different between the two groups. 
However, there was a tendency towards a higher IFN-γ/IL-4 ratio in the lower inoculum group. 
Therefore, a potential influence of the inoculum size over cell-mediated responses of R. equi 
infected foals should not be completely discarded.  
 CTL activity has been investigated in immunocompetent foals102. As suspected, CTL 
activity was shown to be deficient in foals younger than 3 weeks. This observation coincides with 
the period of time when foals are first exposed to a contaminated environment. At 6 weeks of age, 
some foals had developed CTL activity, although not as efficient as in adult horses. At 8 weeks of 
age, all foals showed significant R. equi-specific CTL activity. In addition, as in adults, killing of 
R. equi targets was not MHCII restricted. These findings suggest that acquisition of CTL activity 
in association with development of protective immune responses may occur due to natural exposure 
and immunological maturation. 
  
Humoral immunity  
Since adult horses are immune and remain clinically normal upon challenge, understanding 
their humoral response to R. equi may help elucidate a protective humoral response. Lopez et al. 
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(2002), challenged 12 adult horses with virulent R. equi and subsequently evaluated serum levels 
of IgGa, IgGb, IgG(T), IgA and IgM against both whole R. equi and recombinant VapA protein. 
While all horses remained clinically sound, levels of R. equi and VapA specific IgGa and IgGb 
were dramatically enhanced at 14 days post-challenge. In another instance, 6 healthy adult horses 
were challenged with R. equi and their humoral response evaluated81. An IgGa-dominant response 
was observed, as well as consistently higher IgGa-to-IgGb and IgGa-to-IgG(T) ratios when 
compared to pneumonic foals.  
VapA specific IgG subisotype responses in healthy exposed foals, and foals with clinical 
R. equi pneumonia have been compared81. Pneumonic foals produced an IgGb-dominant response 
to VapA, which was significantly greater than in healthy, exposed foals. Whereas the IgG 
subisotype response of pneumonic foals trended toward higher IgG(T) compared to clinically 
normal foals, IgGa was significantly higher in the clinically normal foals. Also, both IgGa-to-IgGb 
and IgGa-to-IgG(T) ratios tended to be higher in healthy, exposed foals. Since in mice and humans, 
the antibody isotype reflects the Th1- Th2 bias of the immune response, the authors concluded that 
a similar bias may occur in horses, and that IgGb and IgG(T) are products of a Th2 response, while 
IgGa is a product of a Th1 response. Furthermore, it was suggested that foals which develop R. 
equi pneumonia have a Th2-biased, ineffective immune response whereas foals which become 
immune develop a Th1-biased immune response.  
Changes over time in VapA specific IgG and IgG subisotypes have been further 
characterized in challenged, naturally infected and not infected foals103. Challenged foals were 
intratracheally infected with 103 cfu/foal of R. equi (206+ UKVDL) at 1, 2 or 3 weeks of age. 
Another group of foals that was not challenged, but was housed in the same pasture as the 
challenged foals, and developed subclinical lung lesions with positive R. equi tissue culture were 
considered naturally infected. Foals that were not challenged, remained disease-free, and had 
negative lung tissue culture for R. equi were considered not infected. All foals were bled at birth 
and weekly thereafter for 8 weeks. Following birth, VapA-specific IgGs significantly decreased 
over time in all foals as a result of normal decay of passively transferred antibodies. Both VapA-
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specific IgGa and IgG(T) significantly increased after experimental challenge, however, the rise in 
IgG(T) occurred earlier. Only a significant increase in VapA-specific IgG(T) over time was seen 
after natural infection. However, due to the terminal nature of this challenge study, the IgG profile 
of foals that developed clinical pneumonia either after challenge or natural infection could not be 
determined. Furthermore, the small sample size of naturally infected foals (n = 6) precluded the 
determination of whether VapA-specific IgG(T) could be used to differentiate rhodococcal from 
other pneumonias under field conditions.  
Most recently, the performance of VapA-specific ELISA for IgG and its subclasses IgGa, 
IgGb and IgG(T) in the early diagnosis of pneumonia caused by R. equi was evaluated104. When 
used to identify infected foals, VapA-specific IgG, IgGa and IgGb had no diagnostic value. In 
contrast, IgG(T) had high sensitivity (90%) and specificity (96%) at a cut-off of 2.7 Elisa Units. A 
major limitation of this study was the lack of definitive diagnosis of naturally infected foals; hence, 
further investigation of this test in field conditions is needed.  
The effect of inoculum size on humoral immune response of foals challenged with R. equi 
has also been studied105. Foals were challenged intrabronchially, between 7-12 days of age, with 
either 106 or 108 cfu inoculum. R. equi-specific IgM, IgGa, IgGb, IgGc, and IgG(T) concentrations 
in serum were determined before infection and on day 15 post-infection. The mean ratios of post-
infection to pre-infection IgG(T) and IgM concentrations were significantly higher in foals infected 
with the greater inoculum, indicating that the inoculum size modulates the humoral response of 
infected foals. 
 
Disease prevention strategies  
Currently used strategies 
Since rhodococcal pneumonia is an insidious disease, clinical signs may not be apparent 
until pathological changes are well progressed1,2. Therapy of all foals affected with subclinical 
disease is not warranted as a recent controlled clinical trial on an endemic farm demonstrated that 
many foals with subclinical pulmonary lesions recover without therapy106. Mass treatment of foals 
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with antibiotics could generate negative consequences for both equine and human medicine due to 
the development of anti-microbial resistance. Consequently, the rationale for screening is that 
detection foals in the early stages of disease will improve therapeutic outcomes. Currently, the most 
widely used methods for prevention of rhodococcal pneumonia rely on highly sensitive but poorly 
specific screening techniques for early detection of pneumonia, and on administration of HIP. The 
latter confers only partial protection, is expensive and may not readily available. Although 
screening for early identification of disease on farms with recurrent history of foals affected by R. 
equi is recommended by the American College of Veterinary Internal Medicine107 , evidence for 
the recommendation is relatively weak, with no supporting controlled studies. 
A variety of screening techniques performed serially have been described, including visual 
inspection of foals, monitoring rectal temperatures, clinical signs of pneumonia or extrapulmonary 
disorders, hematological parameters, serology, and thoracic imaging using either radiography or 
ultrasonography, with empiric recommendation that screening begin around 3 weeks of age108. 
Some tests appear to be ineffective for screening, such as serum concentrations of R. equi specific 
IgG, serum amyloid A, or plasma fibrinogen109–112. White blood cell (WBC) counts performed at 
monthly intervals appeared to have clinically acceptable sensitivity and specificity for early 
detection of R. equi pneumonia at 1 farm112. Limitations of using WBC for screening are the time 
and effort required to collect blood samples, possible lag from time of submission, and the potential 
for false-positive results attributable to other infectious or inflammatory conditions that may be 
common among foals, or to stress-associated leukocytosis. Use of thoracic ultrasonography as a 
screening tool offers a number of advantages: it can be quickly learnt and performed, provides 
immediate results, and has a greater specificity for detection of pulmonary disease compared to 
WBC. However, the main disadvantage of a highly sensitive screening program is an increase in 
apparent incidence of disease, leading to an increased number of foals treated for presumptive R. 
equi pneumonia. As the proportion of which foals might recover spontaneously remains unkown, 
and because R. equi infections can cause severe disease, many breeding farms elect to treat all foals 
with positive results of screening tests. This approach has had more than a significant negative 
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financial impact in the equine industry worldwide. Overtreatment of foals over the past decade has 
led to an alarming emergence of multi-drug resistant R. equi on different continents113,114, indicating 
immediate need for efficient disease prevention rather than reliance on treatment.  
Administration of commercially available hyperimmune plasma (HIP) products containing 
antibodies against R. equi is heavily relied upon as a disease preventive measure. Despite the 
historical controversy regarding the efficacy of HIP, its use has generally proved effective in 
significantly reducing the severity of R. equi pneumonia in foals following experimental 
challenge115–119. However, studies evaluating the efficacy of various HIP preparations under field 
conditions have shown equivocal results120–122. Many factors may account for these disparate results 
such as differences in hyperimmunization protocol, study design, clinical outcome assessment, and 
timing of administration. Most recently, a lack of product uniformity among the different 
commercially available R. equi HIP products in the US was reported123. VapA specific IgGs were 
significantly different between products and varied between lots of the same product, with 
coefficients of variation ranging from 17 to 123%. These results may also explain previously 
reported disparities in HIP efficacy.  
Neither the optimal amount, the number of doses, or the foal’s age at HIP administration 
time has been determined. Administration of HIP at 7 and 9 days after aerosol infection of foals 
with R. equi did not confer protection, suggesting that its administration prior to infection may be 
of importance124. Because of evidence that many foals become infected early in life, it is commonly 
recommended that foals receive transfusion of at least 1 liter of HIP within the first 24-48 hours 
after birth21,24,107. The rationale for administering a second dose of HIP at 2-4 weeks of age is based 
on the possibility that early administration of HIP may result in the decline of passively transferred 
antibodies to a non-protective level at a time foals are still susceptible to R. equi.  
 
Vaccine 
For decades, numerous attempts have been made to develop an effective vaccine for use in 
foals that is safe, immunogenic and efficacious. However, R. equi vaccine candidates based upon 
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the traditional vaccine platforms such as live125, killed126,127 and attenuated128 have not been 
successful. Modern molecular based vaccines, such as DNA129,130, subunit131 and genetically 
attenuated132,133R. equi have shown some potential, however, these vaccines have not conferred 
protection in mice. More recently, bacterial vector vaccines have shown positive results in murine 
models134–136, but are yet to be further developed and shown to be protective in foals.  
The most difficult challenge yet to be overcome is the need to vaccinate foals at a very 
young age, with a vaccine that will benignly modulate their naïve, immunodeviant immune system 
generating an effective immunity within the first week of life.  
 
Research Hypotheses 
 Despite all the efforts that have been directed towards a better understanding of the foal’s 
immune response to R. equi, much remains unknown. In an attempt to make a positive contribution 
not only to the existing research body, but also to impact the routine of those who deal with R. equi 
in the field, my research has focused on seeking improved diagnostic and preventive tools. 
Therefore, the following hypotheses are proposed: 
H1 – Specific anti-VapA IgG(T) is a marker of clinical disease in infected foals. (Chapter 2) 
H2 – Cytokine expression profile in whole blood of progressor and regressor foals is significantly 
different. (Chapter 3) 
H3 – Higher levels of passively acquired VapA antibodies delivered by HIP are associated with 
disease regression in naturally exposed foals. (Chapter 4) 
H4 – Specific Rhodococcus equi pili antibodies passively acquired by foals via colostrum ingestion 
from mares previously immunized with a pili-based candidate vaccine confers protection against 
induced rhodococcal pneumonia.  
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CHAPTER 2 
VAPA SPECIFIC IGG(T) WAS NOT A RELIABLE PREDICTOR OF CLINICAL 
PNEUMONIA IN FOALS AFTER CHALLENGE OR NATURAL INFECTION WITH R. EQUI 
 
Introduction 
Rhodococcus equi, a gram-positive facultative intracellular pathogen, has worldwide 
importance as a cause of pneumonia in young foals107. There is no commercially available vaccine 
against rhodococcal pneumonia, and although controversial, intravenous administration of R. equi 
hyperimmune plasma (HIP) shortly after birth is commonly practiced in an attempt to prevent 
disease. Control of R. equi pulmonary infections currently relies on early detection of disease using 
thoracic ultrasonography and initiation of treatment with antimicrobial agents prior to the 
development of clinical signs. This approach is highly sensitive; however, it lacks specificity. In 
particular, it fails to differentiate infected foals in which disease will progress and become 
symptomatic (progressors) from the majority of infected foals in which lung lesions will regress 
and spontaneously resolve, as they remain free of symptoms of pneumonia (regressors)106. Use of 
a low ultrasonographic score threshold to guide therapeutic decision has led to overtreatment of 
foals, and most importantly, to multi-drug bacterial resistance worldwide affecting not only horses 
but also immune-compromised humans 137–139 . 
While little is known about the factors that determine susceptibility of foals for 
development of rhodococcal disease, it is likely that protection involves opsonizing antibodies. 
Specifically, immunoglobulin G (IgG) antibodies are thought to be important since entry of R. equi 
into macrophages mediated by Fcγ receptors leads to enhanced bacterial killing12,14,81,82. 
Furthermore, an increase in serum IgG against R. equi is observed after natural exposure and oral 
or intra-tracheal inoculation103,140,141. However, not all IgG subisotypes are equally effective. 
Although IgG(T) has been shown to be a potent complement activator in horses, a VapA specific 
IgG(T) response was not seen after natural exposure of adult horses or healthy foals, and it has been 
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typically associated with a non-protective T helper 2 (Th2) immune responses in R. equi-infected 
foals81,83. 
Recently, it has been demonstrated that an early response to experimental infection of 
neonatal foals using a low dose (103 cfu/foal), as well as to natural infection, is characterized by a 
significant increase in specific  IgG(T) at 5-8 weeks of life103. Furthermore, when compared to IgG, 
IgGa, and IgGb, IgG(T) was shown to be the best predictor of R. equi infection in either 
experimentally challenged or naturally infected foals104. Despite the low number of naturally 
infected foals in the first study, and the lack of confirmed diagnosis of the presumptively naturally 
infected foals included in the second study, these findings suggest that IgG(T) may be useful to 
differentiate rhodococcal from other causes of pneumonia affecting young foals. However, further 
research is needed to evaluate VapA specific IgG subisotypes as potential markers for the 
development of clinical disease. 
In light of the challenge that identification of progressor foals currently presents, the main 
objective of this study was to investigate the use of IgG(T) to identify progressor foals among the 
R. equi-infected population. Therefore, our hypotheses were three-fold: (1) serum concentrations 
of IgG(T) are significantly higher in progressor foals than in regressor foals, after challenge or 
natural infection; (2) IgG(T) is a reliable predictor of disease outcome in naturally infected foals; 
and (3) IgG(T) outperforms other IgG subisotypes in predicting clinical pneumonia in naturally 
infected foals. 
 
Materials and Methods 
R. equi challenge  
Two low-dose challenge studies were performed in subsequent years (2016 and 2017), 
using modifications of the previously described infection model24. R. equi 103+ was provided by 
Bioniche Animal Health. The bacteria were stored as a frozen stock in 20% glycerol and streaked 
onto a tryptic soy agar yeast extract (TSAYE) plates and incubated for 48 hours at 37°C. A single 
typical mucoid, creamy colony was selected from the plate, inoculated into tryptic soy yeast broth 
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(TSBYE) and incubated for another 48 hours at 37°C. Bacterial concentration was initially 
estimated based on optical density (OD) of the culture media using a spectrophotometer at 600nm 
wavelength and confirmed by serial dilution plating. All isolates were tested for the VapA-carrying 
plasmid using PCR at the UKVDL. The agar plates were held at room temperature for an additional 
72 hours when colony morphology was evaluated. Culture medium was serially diluted using sterile 
PBS to obtain a total concentration of bacteria of 104 cfu/ml. One ml of 104 cfu/ml was used to 
inoculate each foal. Inocula were kept refrigerated during transportation to the farm, and until 
challenge was performed. An additional inoculum sample that had been taken to the farm, was 
plated onto TSAYE plates once back in the laboratory, in order to confirm bacterial viability and 
concentration. 
 Foals were challenged at 3-7 days of age following confirmation of optimal passive 
transfer.  Foals were deemed clinically healthy based on a normal complete blood cell (CBC) count, 
fibrinogen and thoracic ultrasonography. Prior to challenge, mare and foals were brought into stalls 
and the foals were sedated using a combination of valium (0.2 mg/kg) and butorphanol (0.05 
mg/kg). A flexible tube was used to deliver bacteria to the mid trachea (intratracheal instillation).  
 Confirmation of R. equi pneumonia was obtained either by collecting post-mortem samples 
from lung lesions, or by performing in vivo trans-tracheal wash 4 weeks after challenge. Subsequent 
aerobic bacterial culture was performed at the UKVDL. Sample collection was discontinued if 
treatment for pneumonia was perceived as necessary based on observation of significant clinical 
signs of pneumonia.    
Sera and HIP samples 
 Sera samples from challenged foals were obtained immediately before, and 2, 4, 6, and 8 
weeks after challenge. None of the challenged foals received HIP. All sera were archived at -20°C 
for batch analysis.  
Potentially naturally infected foals were located on R. equi-endemic farms in the central 
Kentucky area. Foals were included in the study if they had adequate passive transfer and were 
deemed clinically healthy at 1 week of age based on history and physical examination. Systemic 
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disease or treatment for respiratory disease was used as exclusion criteria. All foals were born 
during the 2017 foaling season. Since all enrolled farms had a history of rhodococcal disease, 
routine administration of 1L of HIPa within 24 hours of birth was practiced. HIP samples were 
collected at administration time. Sera samples were also collected from each foal’s dam at the time 
of HIP administration. Sera samples from the foals were collected by the farm’s veterinarian at 7 
days (timepoint 1), and at 1, 2 and 3 months of age (timepoints 2-4). Serum was also collected 
when a foal developed specific signs of pneumonia, and a diagnosis of R. equi pneumonia was 
made based on the presence of one or more specific clinical signs of pneumonia and detection of 
lesions by ultrasonography (See “Foal evaluation and classification”). All sera were archived at -
20C for batch analysis. 
Foal evaluation and classification 
 After challenge, mares and foals returned to pasture and were evaluated for 8 weeks. Foals 
were observed daily for increased respiratory rate or effort, mucoid or purulent nasal discharge, 
lethargy and anorexia. Rectal temperature was recorded twice a day. Complete physical 
examination was performed twice a week in order to detect specific signs of pneumonia, including 
increased respiratory rate and effort, abnormal lung sounds on thoracic auscultation, presence of 
purulent nasal discharge, presence of spontaneous cough and presence of submandibular and/or 
retropharyngeal lymph node enlargement. In order to objectively assess respiratory disease 
severity, a scoring system was designed (Table 2.1). Bilateral lung ultrasonography was performed 
prior to, and biweekly after challenge using a 7.5MHz linear probe (CTS-7700V-SIUI, Universal 
Medical System Inc., Bedford Hills, NY). In order to monitor disease progression, each lung was 
scored based on the sum of the maximum diameters of each lesion, and a total score was obtained 
by adding both lung scores. All physical and ultrasound examinations of challenged foals were 
performed by the author.   
 
                                                     
a MgBiologics, Ames, IO, USA. 
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Table 2. 1 Physical examination scoring system. F = Fahrenheit degrees; bpm = breaths per minute; 
LNs = lymph nodes; *to be scored according to the severity of the abnormal lung sounds.  
   Potentially naturally infected foals were physically examined at 7 days of age. Thereafter, 
physical and lung ultrasonographic examinations were performed at 1, 2 and 3 months of age, or 
when specific clinical signs of pneumonia developed. While the same physical examination and 
lung ultrasonographic parameters and guidelines were used to evaluate challenged and naturally 
infected foals, four different veterinarians performed the examinations and assigned the respective 
scores to the naturally infected foals.  
Experimentally and naturally infected foals were categorized as regressors based on the 
presence of ultrasonographic lesions compatible with rhodococcal pneumonia142, that 
spontaneously resolved over time, in the abscence of any specific clinical signs of pneumonia or 
medical treatment. Based on the presence of one or more specific clinical sign(s) of lower 
respiratory infection in addition to ultrasonographic lesions compatible with rhodococcal 
pneumonia, foals were categorized as progressors. For potentially naturally infected foals, if 
neither ultrasonographic lesions compatible with rhodococcal pneumonia or specific clinical 
sign(s) of lower respiratory infection were detected over the first 3 months of life, they were 
categorized as no respiratory abnormalities or NRA.  
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VapA Purification 
Recombinant VapA protein was produced and purified using an Escherichia coli strain that 
contained a VapA plasmid fused to glutathione-S-transferase, as previously described82. The purity 
of the protein was assessed by sulfate-polyacrylamide gel electrophoresis (SDS-page)b.   
Source of reference control sera 
 Positive and negative control sera were included on each ELISA plate. Serum from a mare 
previously vaccinated with killed VapA+ R. equi was used as positive control. Negative control 
serum included fetal equine serum (FES) and serum obtained from a 4-month old foal whose 
necropsy and lung tissue culture results were negative for R. equi. Commercially available R. equi 
specific hyperimmune plasmas were used to construct standard curves. The standard curves for 
IgG, IgGa, and IgGb were constructed using one product (ReSolution)c while a different one 
(EquiplasRea)d was used for IgG(T). All reference sera were divided into 100uL aliquots and stored 
at -20C until used. 
VapA-specific enzyme-linked immunoabsorbent assay 
 The ELISA for IgG was based on previously described methods 81,104,140. Briefly, 96-well 
microplatese were coated with VapA (0.5ug/well) in carbonate bufferf and allowed to incubate 
overnight at 4C. Afterwards, a mixture of blocking buffer (polyvinyl alcohol [Mowiol 6-98] 1% 
[w/v] in distilled water) and phosphate-buffered saline (PBS, to a final concentration of 1:1 [v/v]) 
was added. Serum was diluted (1:100) in PBS with 0.05 Tween-202 (PBST), added to duplicate 
wells and incubated at 37C for 1 hour. Either goat anti-horse IgG conjugated with horseradish 
peroxidase (HRPg; 1:10,000 dilution) or murine anti-IgGa (1:2 dilution, CVS48), anti-IgGb (1:5 
dilution, CVS39), or anti-IgG(T) (1:2 dilution, CVS40; all hybridomas provided by P. Lunn, North 
Carolina State University) were then added and incubated for 1 hour at 37C. The IgG subisotypes 
                                                     
b Bio-Rad, Philadelphia, PA, USA. 
c MgBiologics, Ames, IO, USA. 
d Plasvacc USA Inc, Templeton, CA, USA. 
e Thermo Scientific, Rochester, NY, USA. 
f Sigma Aldrich, St. Louis, MO, USA. 
g Jackson ImmunoResearch, West Grove, PA, USA. 
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plates were washed, and goat anti-mouse IgG-HRPh (1:2000 dilution) added for an additional hour 
at 37C. Plates were washed between each step with PBST using an ELISA plate washer (MW 
96/384)i. The substrate (3,3’,5,5’-tetra-methylbenzidine, peroxidase substrate)j was then added for 
5 minutes. The reaction was stopped using stop solutionk. Absorbance was read at 450 nm using an 
ELISA plate readerl. Results were converted to ELISA units (EU) using a logarithmic trend line 
from the standard curve generated for IgG and each subisotype143. A coefficient of determination 
(r2) of ≥ 0.90 for the standard curve was required for the results to be considered valid144.  
Statistical Analysis 
Data collected from the challenge studies was analyzed using commercial software 
(SigmaPlot, SPSS, Chicago, IL, USA). Average physical and lung ultrasonography scores were 
compared between progressor and regressor groups at each timepoint using Student’s t-test. 
Physical examination and lung ultrasonography scores from regressor and progressor foals were 
compared with respect to their IgG profiles expressed as ELISA Units (EU) using Pearson 
correlation coefficient. IgG profiles were compared overtime, and between progressor and 
regressor groups using two-way repeated measures ANOVA.  
Data collected from naturally infected foals were analyzed using commercial softwares 
(SigmaPlot, SPSS, Chicago, IL, USA). Maternal serum and HIP IgG profiles were compared 
among the three groups of foals using ANOVA on ranks. Average physical and lung 
ultrasonography scores were compared between progressor, regressor and NRA groups at each 
time-point using one-way ANOVA. Physical examination and lung ultrasonography scores from 
regressor, progressor, and NRA foals were compared to their IgG profile expressed as ELISA Units 
(EU) using Pearson correlation coefficient. VapA IgG profile was compared overtime, and between 
regressor, progressor, and NRA groups using two-way repeated measures ANOVA.  
                                                     
h Bethyl Laboratories, Inc, Montgomery, TX 77356 USA 
i Beckman Coulter, Brea, CA, USA. 
j KPL, Gaithersburg, MD, USA. 
k KPL, Gaithersburg, MD, USA. 
l Bio-Rad, Philadelphia, PA, USA. 
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In order to evaluate the potential use of IgG(T) as a field diagnostic test, only samples 
collected under field conditions were used to evaluate the diagnostic performance of the different 
IgG subisotypes and total IgG. Logistic regression and receiver operating characteristic (ROC) 
curves were used to assess the overall diagnostic performance of each IgG subisotype and total IgG 
at each timepoint, and as the sum of each IgG subisotype and total IgG produced over the first 3 
months of life (time-points 2-4). In order to evaluate the diagnostic performance of each IgG 
subisotype and total IgG to identify progressor foals among the infected population, ROC curves 
were constructed using progressors and regressor foals at each timepoint, and also using the paired 
results from the first 3 months of life.  
Significance was set at P<0.05.  
 
Results 
Challenged foals 
 Twenty-two and 14 foals challenged in the years of 2016 and 2017, respectively, were 
included. The median age at challenge was 4.6 days, and the inoculum per foal ranged from 12,600-
25,200 cfu. Bacterial isolates used to challenge the foals were VapA-positive and developed typical 
colonies on TSAYE plates, when plated either before or shortly after challenge. Ultrasonographic 
lesions consistent with R. equi pneumonia were observed in all foals after challenge. Time of 
ultrasonographic lung lesion appearance varied from 3 to 4 weeks after challenge. During the first 
challenge study 6 randomly selected foals were euthanized and necropsied (4 progressor and 2 
regressor foals). Time of euthanasia varied from 4 to 7 weeks after challenge. R. equi pneumonia 
was confirmed in all 6 foals. During the second challenge study 2 foals were treated for rhodococcal 
pneumonia. Transtracheal wash was performed in all foals included in this study, and R. equi 
culture of the obtained fluid yielded positive growth in 26 (72%) foals. Only in one foal R. equi 
culture was accompanied of Streptococcus equi zooepidemicus. Non-pathogenic bacteria were 
isolated from the remaining 10 foals. Overall, 12 foals were classified as progressors, and 24 foals 
as regressors.  
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Average physical examination and lung ultrasonographic scores were significantly 
different between progressor and regressor foals (Figs. 2.1 and 2.2).  
 
 
Figure 2. 1 Average physical examination scores of progressor and regressor foals before and after 
R. equi challenge at physical examination times 1-16. * indicates statistical difference between 
groups.  
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Figure 2. 2 Average lung ultrasonographic scores of progressor and regressor foals before and after 
R. equi challenge at physical examination times 1-16. * indicates statistical difference between 
groups. 
 
Significant correlations were found between IgGa and physical examination (p = 0.0431) 
and lung ultrasonography (p = 0.0185) at four weeks after challenge, and also between total IgG 
and lung ultrasonography scores (p = 0.0121), and IgGb and lung ultrasonography scores (p = 
0.0052) at six weeks after challenge (Table 2.2).  
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Table 2. 2 Pearson correlation coefficient between the IgG profile of progressor and regressor foals 
and their physical examination (PE score) and thoracic ultrasound (US score) scores. * indicates 
significant correlation between variables. 
 
Progressor foals had significantly higher total IgG than before challenge (p = 0.007), and 
higher than regressor foals 8 weeks after challenge (p = 0.013) (Fig. 2.3). Progressor foals had 
significantly higher IgGa than before challenge at 6 (p = 0.004) and 8 (p = 0.003) weeks after 
challenge, and than regressor foals also at 6 (p = 0.003) and 8 (p = 0.004) weeks after challenge 
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(Fig. 2.4). Progressor foals had significantly higher IgGb than before challenge at 6 (p = 0.02) and 
8 (p = 0.002) weeks, and to regressor foals also at 6 (p = 0.04) and 8 (p = 0.018) weeks after 
challenge (Fig. 2.5). Although progressor foals had increased IgG(T) at 6 weeks after challenge, no 
significant differences were detected between groups at any timepoint, or overtime within each 
group (p = 0.101) (Fig. 2.6). The IgG profile means and standard deviations for progressor and 
regressor foals at each timepoint are shown in Table 2.3. 
 
 
Figure 2. 3 Total VapA specific IgG of progressor and regressor foals before (PC = pre-challenge), 
and 2 (2w), 4 (4w), 6 (6w), and 8 (8w) weeks after challenge. Bars represent sample standard 
deviation. *indicates statistical difference between groups; letter “a” indicates statistical difference 
between pre-challenge values within progressor group.  
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Figure 2. 4 VapA specific IgGa of progressor and regressor foals before (PC = pre-challenge), and 
2 (2w), 4 (4w), 6 (6w), and 8 (8w) weeks after challenge. Bars represent sample standard deviation. 
*indicates statistical difference between groups; letter “a” indicates statistical difference between 
pre-challenge values within progressor group. 
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Figure 2. 5 VapA Specific IgGb of progressor and regressor foals before (PC = pre-challenge), and 
2 (2w), 4 (4w), 6 (6w), and 8 (8w) weeks after challenge. Bars represent sample standard deviation. 
*indicates statistical difference between groups; letter “a” indicates statistical difference between 
pre-challenge values within progressor group. 
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Figure 2. 6 VapA specific IgG(T) of progressor and regressor foals before (PC = pre-challenge), 
and 2 (2w), 4 (4w), 6 (6w), and 8 (8w) weeks after challenge. Bars represent sample standard 
deviation. 
 
 
Table 2. 3 Mean (± SD) VapA specific IgG profile of progressor and regressor foals before (PC) 
and 2 (2w), 4 (4w), 6 (6w) and 8 (8w) weeks after challenge.   
 
Naturally infected foals 
 Ninety-eight sample sets consisting of foal serial sera, dam’s sera and HIP samples, were 
studied. Fourteen foals were classified as progressors, 6 as regressors, and 78 as NRAs.  
Progressor Total	IgG SD IgGa SD IgGb SD IgG(T) SD
PC 1.07 0.71 1.45 0.52 2.37 0.99 1.31 0.11
2w 0.72 0.25 1.38 0.30 2.11 0.57 1.41 0.12
4w 2.19 2.29 20.44 28.84 3.73 3.16 7.26 7.61
6w 5.74 7.25 70.49 157.30 11.45 14.09 14087.45 44399.59
8w 8.46 8.33 87.12 154.59 15.67 14.02 711.19 1380.53
Regressor Total	IgG SD IgGa SD IgGb SD IgG(T) SD
PC 3.99 9.78 4.03 6.39 6.86 14.22 1.37 0.13
2w 1.74 2.42 2.28 2.14 3.55 3.83 1.38 0.10
4w 1.94 1.24 9.62 11.08 3.98 2.17 1726.51 5839.61
6w 2.65 1.86 11.15 10.01 5.54 3.83 321.86 905.07
8w 2.99 2.29 11.78 10.74 7.21 6.17 546.38 1740.01
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No significant statistical differences were detected between IgG profiles from the dams of 
progressor, regressor and NRA foals. However, HIP received by progressor (p = 0.011) and 
regressor (p = 0.021) foals had significantly higher amounts of IgGa than the HIP administered to 
the NRA foals (Fig. 2.7). Similarly, the HIP received by progressor (p = 0.036) and regressor (p = 
0.049) foals also had significantly higher amounts of IgGb than the HIP administered to the NRA 
foals (Fig. 2.8). 
 
  
Figure 2. 7 VapA specific IgGa in HIP received by naturally exposed foals (progressor, regressor, 
NRA). Bars represent sample standard deviation *indicates statistical difference in comparison to 
the NRA group.  
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Figure 2. 8 VapA specific IgGb in HIP received by naturally exposed foals (progressor, regressor, 
NRA). Bars represent sample standard deviation *indicates statistical difference in comparison to 
the NRA group.  
 
Average physical examination and thoracic ultrasonographic scores were significantly 
higher for progressor than NRA foals at timepoints 3 (p = 0.027) and 4 (p < 0.001). No significant 
correlations were found between the IgG profile of progressor and regressor foals and their physical 
examination and thoracic ultrasonographic scores (Table 2.4).  
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Table 2. 4 Pearson correlation coefficient between VapA specific IgG profile of progressor and 
regressor foals and their physical examination (PE score) and thoracic ultrasound (US score) scores.  
 
There were no significant total IgG differences between groups (Fig. 2.9). Progressor foals 
had significantly higher titers of IgGa in comparison to regressor foals at timepoint 2 (p = 0.015) 
(Fig. 2.10). Progressor foals also had significantly higher titers of IgGb than regressor foals at 
timepoints 1 (p = 0.036), and significantly higher than regressor (p = 0.04) and NRA (p = 0.045) 
foals at timepoint 2. NRA foals had significantly higher titers of IgGb than regressor foals at 
timepoint 2 (p = 0.036) (Fig. 2.11). Finally, progressor foals had significantly higher titers of 
IgG(T) than NRA foals at timepoint 3 (p <0.001) (Fig. 2.12). Differences in IgG profiles within 
each group of foals overtime are indicated on the figures (Figs. 2.9-12). The IgG profile means and 
Total	IgG IgGa IgGb IgG(T)
All	P	and	R PE	Score -0.1315 -0.1737 0.0422 -0.0506
US	Score -0.2618 -0.3163 0.3283 0.0911
Progressors PE	Score -0.2691 -0.3730 -0.0872 -0.0832
US	Score -0.4300 -0.3699 -0.3513 -0.0142
Regressors PE	Score N/A N/A N/A N/A
US	Score -0.3429 -0.1985 -0.0692 -0.3028
Total	IgG IgGa IgGb IgG(T)
All	P	and	R PE	Score -0.1565 -0.0941 -0.2468 0.7061
US	Score -0.0600 -0.0109 -0.1859 0.5484
Progressors PE	Score -0.4005 -0.2760 -0.5853 0.7462
US	Score -0.2045 -0.1542 -0.4406 0.5609
Regressors PE	Score N/A N/A N/A N/A
US	Score -0.5349 0.1464 -0.4572 0.3316
Total	IgG IgGa IgGb IgG(T)
All	P	and	R PE	Score 0.6907 0.6031 0.7196 0.0538
US	Score 0.1629 0.3201 0.3684 0.5926
Progressors PE	Score 0.5498 0.5083 0.5210 0.0159
US	Score -0.0447 0.2666 0.2468 0.6585
Regressors PE	Score 0.0709 0.0857 -0.2409 -0.5610
US	Score 0.9077 0.0818 0.4352 0.4509
TP2
TP3
TP4
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standard deviations for progressor, regressor and NRA foals at each timepoint are shown in Table 
2.5. 
 
  
 
Figure 2. 9 Total VapA specific IgG of progressor, regressor, and NRA foals over time (1,2,3 and 
4 sample collection time points). Bars represent sample standard deviation. Letter “a” indicates 
statistical difference between pre-challenge values within NRA group. 
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Figure 2. 10 VapA specific IgGa of progressor, regressor, and NRA foals over time (1,2,3 and 4 
sample collection time points). Bars represent sample standard deviation. *indicates statistical 
difference between progressor and regressor groups; letters “a” and “b” indicate statistical 
difference between pre-challenge values within NRA and progressor group, respectively. 
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Figure 2. 11 VapA specific IgGb of progressor, regressor, and NRA foals over time (1,2,3 and 4 
sample collection time points). Bars represent sample standard deviation. *indicates statistical 
difference between progressor and regressor groups; letters “a” and “b” indicate statistical 
difference between pre-challenge values within NRA and progressor groups, respectively. 
 
 
Figure 2. 12 VapA specific IgG(T) of progressor, regressor, and NRA foals over time (1,2,3 and 4 
sample collection time points). Bars represent sample standard deviation. # indicates statistical 
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difference between progressor and NRA groups; letter “b” indicates statistical difference between 
pre-challenge values within progressor group. 
 
 
Table 2. 5 Mean and standard deviation (SD) VapA specific IgG profile of progressor, regressor 
and NRA foals at timepoints 1-4. 
 
 
Logistic regression indicated that IgGa and IgGb at timepoint 2, and also the sum of IgGa 
and IgGb produced over the first 3 months, were predictors of outcome (progressor versus regressor 
foals) (Table 2.6), as illustrated by the respective ROC curves (Figs. 2.13-15). Both total IgG and 
IgG(T) were poor predictors of outcome at each timepoint, and as the sum of total IgG and IgG(T) 
produced over the first 3 months (Table 2.6). 
Progressor Total	IgG SD IgGa SD IgGb SD IgG(T) SD
Time	point	1 99.45 40.81 111.42 93.45 268.16 210.90 4.47 3.33
Time	point	2 91.21 49.20 98.22 57.67 253.01 159.37 3.81 2.07
Time	point	3 63.44 33.91 61.41 38.86 117.25 58.98 20.14 56.30
Time	point	4 54.99 40.57 37.70 27.24 89.16 59.85 3.16 2.28
Regressor Total	IgG SD IgGa SD IgGb SD IgG(T) SD
Time	point	1 65.92 58.66 66.05 42.00 132.80 81.29 5.11 3.50
Time	point	2 98.75 150.12 28.78 22.56 78.82 54.50 3.70 3.64
Time	point	3 34.94 30.14 33.42 14.98 51.06 32.79 12.28 19.62
Time	point	4 22.78 15.14 22.12 16.82 29.64 16.10 2.48 1.28
NRA Total	IgG SD IgGa SD IgGb SD IgG(T) SD
Time	point	1 96.34 51.84 74.66 41.37 200.43 107.09 4.25 3.05
Time	point	2 80.17 56.03 77.92 59.50 191.28 146.55 4.41 4.79
Time	point	3 60.54 47.77 49.30 62.03 101.97 80.06 4.96 9.44
Time	point	4 38.75 41.32 28.47 27.59 69.51 75.49 4.31 6.74
42 
 
 
Table 2. 6 Logistic regression of progressor versus regressor foals predicted by each single and 
paired parameter. * indicates variable as significant outcome predictor. 
Parameter Time point Estimate** P value AUC for ROC curve model
Total IgG 1 0.00941 0.1786 0.7262
2 -0.00054 0.8751 0.3214
3 0.0175 0.1284 0.7455
4 0.0441 0.1011 0.1011
Paired (2-4) 0.00313 0.4278 0.69
IgGa 1 0.00714 0.2646 0.5952
2 0.0416 *0.0239 0.8929
3 0.027 0.1237 0.7636
4 0.0224 0.2376 0.7
Paired (2-4) 0.0159 *0.0496 0.82
IgGb 1 0.00594 0.1591 0.6905
2 0.0119 *0.0338 0.8929
3 0.0177 0.0532 0.8364
4 0.0539 0.0576 0.9
Paired (2-4) 0.00761 *0.043 0.89
IgG(T) 1 -0.0369 0.6834 0.5595
2 0.9359 0.9359 0.625
3 0.00286 0.7235 0.5273
4 0.1428 0.492 0.492
Paired (2-4) 0.00308 0.8156 0.45
**Analysis of maximum likelihood estimates
Logistic regression of progressor vs regressor foals predicted by listed parameters
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Figure 2. 13 ROC curve analysis of VapA specific IgGa at timepoint 2 as a predictor of clinical 
disease (progressor) among R. equi infected foals (progressors and regressors). The area under the 
curve in indicated on the graph. 
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Figure 2. 14 ROC curve analysis of VapA specific IgGb at timepoint 2 as a predictor of clinical 
disease (progressor) among R. equi infected foals (progressors and regressors). The area under the 
curve in indicated on the graph. 
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Figure 2. 15 ROC curve analysis total VapA specific IgG and IgG subisotypes serially measured 
over the first 3 months of life as predictors of clinical disease (progressor) among R. equi infected 
foals (progressors and regressors). The areas under the curve (A) are indicated on the graph.  
 
Discussion 
 Consistent with previous reports81,103, our results demonstrate that infected foals, either 
after challenge or natural infection, had an increased production of IgG(T) (Tables 2.3 and 2.5). 
The peak of IgG(T) production in either group occurred within the same age range (6-8 weeks of 
age), suggesting that the experimental model was successful in mimicking the timing of natural 
infection. Although challenged and naturally infected progressor foals had higher IgG(T) titers 
compared to the respective regressor and NRA groups, these differences reached statistical 
significance only among the naturally infected foals, during the second month. Clinically, this result 
has no value since thoracic ultrasonography remains the most practical and sensitive tool to detect 
early infection. The decreasing IgG(T) titer observed after it peaked in challenged and naturally 
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infected progressor foals did not indicate a decrease in IgG(T) production, but was due to the loss 
of samples from euthanized and treated foals (Fig. 2.6).  
When IgG(T) was further evaluated as a possible marker of progressor foals among the 
naturally infected population, the results indicated that it failed to predict the development of 
clinical disease (Table 2.6). Overlap in individual titers between progressor and regressor groups 
indicated the limited value of this assay for diagnostic purpose (Table 2.5). Therefore, IgG(T) was 
not a reliable predictor of clinical pneumonia in the naturally infected foals on any of the sampling 
times. In addition, diagnostic accuracy was not increased by testing serial serum samples collected 
over the first 3 months of life in the studied populations.  
Furthermore, IgG(T) did not outperform the other IgG subisotypes in predicting clinical 
disease among infected foals (Fig. 2.15). Instead, IgGa and IgGb measured either during the first 
month of life or as serial serum samples, were the most reliable indicators of progressor foals in the 
studied population (Table 2.6 and Fig. 2.15). However, this finding may have been confounded by 
the passive immunity acquired via HIP, as it was not possible to eliminate its contribution to the 
titers. Despite encouraging results from the challenge study indicating that IgGa and IgGb may 
serve as clinical disease markers among infected foals, confirmatory field studies including foals 
that did not receive HIP are necessary before its use as a diagnostic tool is recommended.  
Previous studies have shown lack of accuracy of serology in differentiating R. equi-affected 
from unaffected foals at time of clinical diagnosis109,110. The poor diagnostic performance of 
serological assays has been attributed to the widespread exposure of foals to R. equi at young ages 
leading to seroconversion without clinical disease. Most recently, IgG(T) has been suggested as a 
potential marker of infection by R. equi either after challenge or natural infection 103. Since 
unchallenged foals were not available, IgG(T) could not be evaluated as marker of infection after 
challenge. Nonetheless, if the challenged progressor and regressor foals were grouped together and 
treated as one group of infected foals, a number of differences in the humoral response after 
challenge were observed when compared to the previous report. Unlike our results, previously 
challenged foals showed a significant decrease in all IgGs at 2-4 weeks after birth that was 
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attributed to decay of passively acquired colostral antibodies. This discrepancy is likely a result of 
varying amounts of VapA specific antibodies carried by the dams in the different studies. A wide 
range of R. equi antibody titers in healthy adult horses has been described140.  In contrast to our 
results, Sanz et al. showed that both IgGa and IgG(T) significantly increased after challenge, and 
only IgG(T) significantly increased after natural infection. In our challenged group of foals, there 
were no significant differences in the IgG profile over time in comparison to pre-challenge values, 
despite the increase of IgG titers after challenge (data not shown). The R. equi strain and dose used 
in the present study were different than previously reported145 which might explain the differences 
in the humoral response from that in the Sanz et al. study. Furthermore, a significant increase in 
IgG(T) was not detected overtime in the naturally infected foals (data not shown) in contrast to 
what was reported by Sanz et al.. Although a definitive diagnosis was not obtained for naturally 
infected foals, the present study included a much larger number of sampled subjects under field 
conditions than previously reported.   
A correlation between disease severity and IgG(T) production may still exist when  
advanced clinical cases are selected, explaining the previous association of IgG(T) with non-
protective responses82. For purposes of this study, administration of treatment for pneumonia was 
a criterion for termination of sample collection, therefore collection of samples from affected foals 
at later stages in the disease process was not performed.  
Although all naturally exposed foals received HIP of the same commercial brand, previous 
reports have documented a lack of homogeneity of commercial HIP146, which might have resulted 
in progressor and regressor foals receiving more IgGa and IgGb than NRA foals. This possibility 
reinforces a need for standardization of HIP products, as well as the importance of cell-mediated 
immune responses to achieve protective immunity. 
As expected, both physical examination and lung ultrasonography scores were 
significantly higher for progressor than regressor foals. In addition, among the challenged foals, 
the significant positive correlations between total IgG, IgGa and IgGb with either score indicated 
that the paired variables increased together. This association is most likely due to the fact that foals 
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with clinical disease (progressor) produced the highest titers of total IgG, IgGa and IgGb at weeks 
6 and 8 after challenge. The lack of significant correlations between IgG(T) and either scores 
emphasizes the dissociation of clinical parameters and IgG(T). 
One marked difference between IgG profiles of challenged and potentially naturally 
infected foals was the overall trend of IgG antibody concentrations. While both populations were 
allowed to nurse ad libitum from their dams, only naturally infected foals received HIP, which 
explains the decreasing antibody titers over time as the exogenous antibodies decayed. Since the 
concentration of circulating IgGs was low in the dam’s sera (data not shown), increasing antibody 
titers over time observed in challenged foals was likely due to seroconversion in response to the 
inoculated R. equi.  
This study had several important limitations, including the limited numbers of naturally 
infected foals that could be classified as progressor or regressor. Pressure to treat foals with small 
ultrasonographic lung lesions limited the number of field samples. Studies including larger sample 
populations of progressor and regressor foals under field conditions where there is less pressure to 
treat subclinically affected foals could yield data more likely to be statistically significant. Another 
limitation of this study was that a definitive diagnosis could not be obtained from naturally infected 
foals. Therefore, our results should be interpreted based on the high positive predictive value of 
ultrasonographically detecting characteristic lung lesions in foals from endemic farms107. Finally, 
although additional equine IgG subisotypes have been described79, we elected to use those 
subisotypes described in prior studies to allow for comparison. Additional work will be needed to 
assess all IgG subisotypes, once specific reagents become available.  
 In conclusion, titers of IgG(T) from progressor and regressor foals greatly overlap, 
regardless of infection mode. Consequently, IgG(T) was not a reliable predictor of disease outcome 
as a single sample measurement, or as a serial sample test over the first 3 months of life. These 
conclusions should be interpreted with caution taking all the study’s limitations into account.  
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CHAPTER 3 
WHOLE BLOOD EXPRESSION OF T CELL MARKERS AND CYTOKINES OF 
PROGRESSOR AND REGRESSOR FOALS CHALLENGED WITH RHODOCOCCUS EQUI  
 
Introduction 
While the majority of foals infected with Rhodococcus equi develop a protective immune 
response and are able to spontaneously recover without showing clinical signs of pneumonia 
(regressors), others exhibit a unique susceptibility to infection which culminates in progressive, 
clinical disease (progressors)106,147. The determining reasons for either outcome are not completely 
understood which hinders development of a highly desirable diagnostic tool capable of 
differentiating between these two populations of infected foals.    
After activation, T cell subsets express different cytokines and mediate distinct effector 
functions during immune responses. Th1 cells are characterized by interferon-gamma (IFN-γ) 
production and are required in defending against infection with many intracellular pathogens148. 
Th2 cells produce interleukin-4 (IL-4) and interleukin-5 (IL-5), and promote development of 
antibody-mediated immune responses against extracellular bacteria and parasites149. Tregs express 
IL-10, and have major functions in maintaining peripheral tolerance, immune regulation, and in 
limiting inflammation during autoimmune diseases150. In addition to distinctive cytokine secretion 
profiles, differential expression of T cell markers provides valuable insight about their diversity.  
It is widely recognized that neonates of different species generally mount poor immune 
responses, particularly a helper T cell type 1 response (Th1) that is crucial for cell-mediated 
immunity76. Neonates often demonstrate an inappropriate bias to a helper T cell type 2 (Th2) 
response151. Without a proper Th1 cell-mediated immune response, neonates have an impaired 
ability to overcome viral and bacterial infections, putting them at risk for infectious diseases26. In 
neonatal and young foals, however, Th-cell responses remain debatable. Although several studies 
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have suggested that the Th-1 immune response of healthy newborn and young foals is 
deficient51,99,152, there is also evidence of the ability of CD4+ and CD8+ T cells to produce adult 
levels of interferon-gamma (IFN-γ) by day 5 after birth in response to in vitro stimulation with 
phorbol myristate acetate (PMA)77. Furthermore, in response to intra-bronchial challenge with 
virulent R. equi, newborn foals were able to mount an INF-γ response with decreased IL-4 
expression similar to that of adult horses101,105,153. 
Regulatory T cells (Tregs) also play a key role in balancing immune responses as they 
regulate immunity after birth and maintain immune tolerance150. Previous reports have 
demonstrated that Tregs are not only prevalent and functional in foals77 but are also able to express 
greater amounts of IL-10 than adult horses following stimulation with lipopolysaccharide (LPS)154. 
Most recently, circulating T regs (CD4+CD25highFoxP3+) have been identified at significantly 
higher concentrations in young foals, and displayed higher suppressive capability than in yearlings 
and adult horses155. These findings support the notion that T-cell responses of healthy foals may be 
biased towards regulatory immune responses. 
To date, neither the whole blood expression of INF-γ, IL-4, IL-5 and IL-10 or of the T 
cell markers for CD4+ (CD4 and MHCII), CD8+ (CD8 and Granzyme B), and Tregs (CD25 and 
FoxP3) of progressor and regressor foals after challenge with R. equi has been evaluated. 
Establishing a better understanding of the immune system of foals is crucial for elucidating the 
susceptibility of young foals to infectious diseases. Here, we characterize the whole blood 
expression of T cell markers and cytokines in foals after experimental infection and search for 
differences between progressor and regressor foals. 
 
Materials and Methods 
R. equi challenge  
Two low-dose infection studies were performed (2016 and 2017), with modifications from 
the previously described infection model24. R. equi 103+ was provided by Bioniche Animal Health. 
The bacteria were stored as a frozen stock in 20% glycerol and streaked onto a tryptic soy agar 
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yeast extract (TSAYE) plate and incubated for 48 hours at 37°C. To prepare the inoculum, a single 
typical mucoid, creamy colony was selected from the plate, inoculated into tryptic soy yeast broth 
(TSBYE) and incubated for another 48 hours at 37°C. Bacterial concentrations were initially 
estimated based on optical density (OD) of the culture media using a spectrophotometer at 600nm 
wavelength and confirmed by serial dilution plating. All the final isolates were tested for the 
presence of VapA-carrying plasmid using PCR at the UKVDL. The agar plates were held at room 
temperature for additional 72 hours at which point colony morphology was evaluated. Culture 
medium was serially diluted using sterile PBS to obtain the total concentration of bacteria of 104 
cfu/ml. One ml of 104 cfu/ml was used to inoculate each challenged foal. The bacterial suspensions 
were kept refrigerated during transportation to the farm, and until challenge was performed. An 
additional aliquot taken to the farm, was later plated onto TSAYE plates in the laboratory, in order 
to confirm bacterial viability and concentration. 
 Foals were challenged at 3-7 days of age if adequate passive transfer had been documented, 
were deemed clinically healthy based on a normal complete blood cell (CBC) count, fibrinogen 
and thoracic ultrasonography. Prior to challenge, mare and foals were brought into stalls and the 
foals were sedated using a combination of valium (0.2 mg/kg) and butorphanol (0.05 mg/kg). A 
flexible tube was used to deliver the bacteria to the mid trachea (intratracheal instillation).  
 Confirmation of R. equi infection was obtained from challenged foals either by collecting 
post-mortem samples from lung lesions, or attempted by performing an in vivo trans-tracheal wash 
4 weeks after challenge. Subsequent aerobic bacterial culture was performed at the UKVDL. 
Foal evaluation and classification 
 After challenge, mare and foal returned to pasture and were evaluated for the following 8 
weeks. Foals were observed daily for increased respiratory rate or effort, mucoid or purulent nasal 
discharge, lethargy and anorexia. Rectal temperature was recorded twice a day. Complete physical 
examination was performed twice a week, in order to detect specific signs of pneumonia including: 
increased respiratory rate and effort, presence of purulent nasal discharge, presence of spontaneous 
cough and presence of submandibular and/or retropharyngeal lymph node enlargement. Bilateral 
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lung ultrasonography was performed on all challenged foals prior to, and biweekly after challenge. 
A 7.5MHz linear probe (CTS-7700V-SIUI, Universal Medical System Inc., Bedford Hills, NY) 
was used for all examinations. All the physical and ultrasound examinations of challenged foals 
were performed by the same veterinarian (F. Cesar).    
Challenged foals were categorized as regressors based on the presence of ultrasonographic 
lesions compatible with rhodococcal pneumonia142, that spontaneously resolved over time, without 
the detection of any specific clinical signs of pneumonia or medical intervention. Based on the 
presence of one or more specific clinical sign(s) of lower respiratory infection in addition to 
ultrasonographic lesions compatible with rhodococcal pneumonia, foals were categorized as 
progressors.  
Sample collection  
 Venous blood samples were collected from foals at 2 and 6 weeks after R. equi challenge. 
Approximately 3ml of blood were collected into Tempus Blood RNA Tubes (Applied Biosystems, 
Foster City, CA – Catalog # 4342792) after which tubes were vigorously shaken for 10-20 seconds 
to ensure adequate cell lysis. All tubes were stored frozen at -20o C for batch analysis.  
Gene expression analysis 
 Total RNA was extracted using the iPrep Total RNA Kit (Invitrogen, Carlsbad, CA- 
Catalog # 59270) and the iPrep Purification Instrument (Invitrogen), per the manufacturer’s 
directions, with the exception that pelleted RNA was resuspended in 600-mL viral lysis buffer 
(Invitrogen - Catalog # 12282500). Gene expression was determined using the relative quantitation 
method156 where averaged results from regressor foals at 2 weeks post-challenge were used as the 
calibrator for each gene. β-Glucuronidase (β-Gus) was used as the housekeeping gene for all 
samples51, and samples were assayed using commercially available primers and probes 
(ThermoFisher Scientific, Waltham, MA): β-Gus (Ec03470630_m1), INF-γ (Ec03468606_m1), 
IL-4 (Ec03468790_m1), IL-5 (Ec03468691_m1),  IL-10 (Ec03468647_m1), CD4 (AI89L0G), 
MHCII(Ec03468998_m1), CD8 (AIQJCBQ), CD25 (Ec03469221_m1), and FoxP3 
(Ec04319948_m1). Relative quantity data were logarithmically transformed before performing the 
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statistical analysis. Amplification data from real time PCR with efficiency outside 90-110% were 
not included.   
Statistical Analysis 
All statistical analyses were carried out using SigmaPlot 13.0 (SPSS Inc., Chicago, IL). 
Two-way analysis of variance (ANOVA) was used to detect significant differences in differential 
gene expression between timepoints and groups. Results were considered statistically significant if 
P≤ .05. 
 
Results 
Challenged foals 
 Twenty-two and 13 foals were challenged in 2016 and 2017, respectively. The median age 
at challenge was 4.6 days, and the inoculum received per foal ranged from 12,600-25,200 cfu. All 
bacterial isolates were VapA-positive and produced typical colonies on TSAYE plates. 
Ultrasonographic lesions consistent with R. equi pneumonia were observed in all foals after 
challenge. Ultrasonographic lung lesion appeared between 3 to 4 weeks after inoculation. During 
the first challenge experiment 6 randomly selected foals were euthanized and necropsied. Time of 
euthanasia varied from 4 to 7 weeks after challenge. R. equi pneumonia was confirmed in all 6 
foals. Transtracheal washes were performed on all foals, of which 26 (72%) were positive for R. 
equi following culture. Streptococcus equi zooepidemicus was also isolated from one of these foals. 
Non-pathogenic bacteria were isolated from the remaining 10 foals. Overall, 13 foals were 
classified as progressors, and 22 foals as regressors.  
Gene Expression 
 While expression of INF-γ (p = 0.019) significantly increased, expression of IL-4 (p = 
0.024), CD4 (p = 0.004), MHCII (p = 0.010), FoxP3 (p < 0.001), and CD25 (p < 0.001) significantly 
decreased over time in challenged foals (Fig. 3.1).  
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Figure 3. 1 Gene amplification measured by RT-qPCR denoted as logarithmic transformed relative 
measure of mRNA expressions (RQ) of IFN-γ , IL-4, CD4, MHCII, FoxP3, and CD25 at 2 (2W) 
and 6 weeks (6W) in all foals after challenge. Bar with asterisk denotes significant difference 
between timepoints. 
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When foals were grouped into progressors and regressors, INF-γ expression significantly 
increased overtime in regressor foals (p = 0.015) (Fig. 2).  Expression of CD4 significantly 
decreased overtime in progressor foals (p = 0.01) (Fig. 2). Expression of MHCII significantly 
decreased over time in regressor foals (p = 0.012) (Fig. 2). Expression of FoxP3 and CD25 
significantly decreased over time in progressor (p < 0.001) and regressor (p < 0.001) foals (Fig. 
3.2). No significant differences in expression of any cytokine or cell marker were detected between 
progressor and regressor at any time.  
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Figure 3. 2 Gene amplification measured by RT-qPCR denoted as logarithmic transformed relative 
measure of mRNA expressions (RQ) of IFN-γ , CD4, MHCII, FoxP3, and CD25 at 2 (2W) and 6 
weeks (6W) in regressor (R) and progressor (P) foals after challenge. Letters “a” and “b” denote 
significant difference between timepoints within regressor and progressor groups, respectively.  
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Discussion 
Our results support previous reports demonstrating a predominant induction of INF-γ 
expression and simultaneous downregulation of IL-4 following R. equi challenge of young foals101 
or in vitro stimulation of their PBMCs with PMA77. When challenged foals were grouped as 
progressors and regressors, a significant increase in differential expression of IFN-γ was observed 
only among regressor foals. Since Th1 cells are characterized by IFN-γ  production and are 
required in defending against infection with many intracellular pathogens148, this response may 
indicate that regressor foals produced a stronger Th1 response after challenge in comparison to 
progressor foals, and successfully controlled the infection. However, since the samples consisted 
of a pool of mRNA from whole blood and not from a specific cell population, the source of the 
INF-γ is unknown. Nonetheless, a significant decrease in differential expression of CD4 was 
observed among progressor foals, reinforcing the idea that CD4+, Th1 cells played a role in the 
production of INF-γ and disease resolution in regressor foals.  
The overall increase in INF-γ  expression with concomitant CD4 and MHCII 
downregulation over time, may indicate that CD8+ T lymphocytes also played a role in producing 
INF-γ in infected foals. By using a flow cytometric method for intracytoplasmic detection of INF-
γ in cell of bronchoalveolar lavage fluid (BALF) from adult horses after challenge, clearance of 
virulent R. equi was shown to be associated with increased numbers of pulmonary CD8+ T 
lymphocytes producing IFN-γ 96. However, no change was observed in IFN-γ-positive cells in 
peripheral blood, implicating a local type 1 recall response in adult horses 96. An accelerated 
development of R. equi specific cytotoxic T Lymphocytes (CTL) has been reported after oral 
inoculation of 3-week old foals with virulent R. equi157. Further, adult-like PBMC expression of 
IFN-γ mRNA by foals stimulated with R. equi lipid antigen or live bacteria has also been reported 
157. At this time, additional sources of IFN-γ mRNA expression by cells of the innate immune 
system cannot be discounted, including γδ T-lymphocytes, NKT cells, or NK cells49.  
Downregulation of the genes (CD4, MHCII, FoxP3 and CD25) in whole blood over time 
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can be explained by either absolute or relative decrease in their expression. Decreased relative 
expression of CD4 and MHCII can be reasoned based on previous reports of decreased CD4+ and 
increased CD8+ cell proportions in peripheral blood of naturally infected foals88. Similarly, a 
relative decrease in FoxP3 and CD25 expression would be expected with aging of the foals as the 
proportion of Tregs in circulation decreases155.  The fact that the expression of both FoxP3 and 
CD25 were significantly lower over time among progressor and regressor foals further supports the 
idea that age drove this response.  
  Ultimately, there were no significant differences in the cytokine and cell marker 
expression profiles of regressor and progressor foals, precluding their use as diagnostic markers for 
disease outcome. However, many possibilities remain to be explored in an attempt to identify 
potential mRNA expression patterns that differ among progressor and regressor foals. Cytokine 
expression profiles of specific cell populations, such as peripheral blood mononuclear cells, should 
be evaluated and compared between these 2 populations of foals.  
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CHAPTER 4  
THE IMPACT OF VAPA IGGS FROM RHODOCOCCUS EQUI HYPERIMMUNE PLASMA 
ON DISEASE OUTCOME AFTER NATURAL EXPOSURE 
 
Introduction  
 Rhodococcus equi, a gram-positive facultative intracellular pathogen, is the most common 
cause of pneumonia in foals between 3 weeks and 5 months of age147. It causes considerable 
economic losses at horse-breeding farms at which infection is endemic. Rhodococcal pneumonia 
in foals is an insidious disease and early diagnosis is not easy. Moreover, despite numerous attempts 
over the past decades to develop a vaccine for use in foals, no vaccine candidate has been shown 
to be effective. In addition, mass treatment of foals with antibiotics may incur serious long-term 
effects such as the induction of multi-drug bacterial resistance, a concern not only for the equine 
industry but also for human medicine, and therefore113,114, is strongly discouraged. Thus the 
importance of disease preventive measures aimed to minimize the financial and welfare impacts of 
R. equi on the equine industry cannot be overstated. 
 Many farms with enzootic rhodococcal pneumonia rely on the use of R. equi specific 
hyperimmune plasma (HIP) as a prophylactic measure. Although the efficacy, protective 
component, or minimum effective dose of R. equi HIP are yet to be established82,121,122,  a great 
number of in vitro, field and challenge study results have supported the protective role of antibodies 
and HIP against R. equi infection14,115–121,146,158–160. HIP administration to foals is usually performed 
within 24-48 hours after birth, as it has been shown that foals that received HIP later in life were 
not protected124. It may also involve the administration of a second dose 4-8 weeks after the first 
dose160, at a time when the foal’s systemic antibodies reach a nadir25.  
  Although R. equi is an ubiquitous soil saprophytic bacterium, virulence requires the 
presence of  plasmid that expresseses virulence-associated protein A (VapA)161. VapA antibodies 
are thought to increase opsonization of R. equi and its killing by phagocytes14,82. Indeed, in vitro 
opsonization of R. equi with immune serum enhanced phagolysossomal fusion and bacterial killing 
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by macrophages14. Likewise, opsonization of R. equi with specific antibodies from commercially 
available HIP promoted phagocytic function of macrophages and neutrophils, increased their 
oxidative burst activity and TNF-alpha production158. Therefore, opsonizing antibodies could be 
important in conferring early protection to young foals, while their cell-mediated immunity 
matures.  
Marked variation in the VapA IgG profile of 4 commercially available R. equi HIP in the 
USA has been reported146. The VapA IgG profile was significantly different between products and 
within three different HIP lots of each product, with coefficients of variation ranging from 17 to 
123%. The wide HIP variation in IgG profile has raised concern among veterinarians, farm owners 
and managers. Further evaluation of the influence of VapA specific IgG profile of HIP profile on 
incidence of rhodococcal pneumonia of naturally exposed foals is warranted.  
The purposes of this study were (1) to determine variation in the IgG profile between 
different units and lots of on HIP product commercially available in the USA, and (2) to identify 
associations between IgG titers in HIP and subsequent development of rhodococcal pneumonia in 
foals on an endemic farm located in central KY, USA.  
  
Material and Methods 
Sera and HIP samples 
 Samples were collected in 2015 and 2016 from all foals born on a Rhodococcus-endemic 
breeding farm in central Kentucky. All foals born received 1L of hyperimmune plasma m 
intravenously within the first 24 hours of life. Foals were excluded from the study if failure of 
passive transfer or systemic illness was detected. Sera were collected at 36-48 hours after 
administration of HIP from all foals and also from their dams at the time of HIP administration. A  
3ml sample of HIP was also collected and kept refrigerated. All samples were stored at -20o Celsius 
for batch analysis. 
 
                                                     
m MgBiologics, Ames, IO, USA. 
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VapA Purification 
Recombinant VapA protein was produced and purified using an Escherichia coli strain that 
contained a VapA plasmid fused to glutathione-S-transferase, as previously described82. The purity 
of the protein was assessed by sulfate-polyacrylamide gel electrophoresis (SDS-page)n.   
Source of reference control sera 
 Positive and negative control sera were included in each ELISA plate. Serum from a mare 
previously vaccinated with killed VapA+ R. equi was used as the positive control. Negative controls 
included fetal equine serum (FES) and serum obtained from a 4-month old foal whose necropsy 
and lung culture results were negative for R. equi. Commercially available R. equi specific 
hyperimmune plasmas were used to construct standard curves. The standard curves for IgG, IgGa, 
and IgGb were constructed using one product (ReSolution)o while a different one (EquiplasRea)p 
was used for IgG(T). All reference sera were divided into 100uL aliquots and stored at -20o Celsius 
until used. 
VapA-specific enzyme-linked immunoabsorbent assay 
The ELISA for VapA-specific IgG was based on previously described methods 81,104,140. 
Briefly, 96-well microplatesq were coated with VapA (0.5ug/well) in carbonate bufferr and allowed 
to incubate overnight at 4C. Afterwards, a mixture of blocking buffer (polyvinyl alcohol [Mowiol 
6-98] 1% [w/v] in distilled water) and phosphate-buffered saline (PBS, to a final concentration of 
1:1 [v/v]) was added. Serum was diluted (1:100) in PBS with 0.05 Tween-202 (PBST), added to 
duplicate wells and incubated at 37C for 1 hour. Goat anti-horse IgG conjugated with horseradish 
peroxidase (HRPs; 1:10,000 dilution) or murine anti-IgGa (1:2 dilution, CVS48), anti-IgGb (1:5 
dilution, CVS39), or anti-IgG(T) (1:2 dilution, CVS40; all hybridomas provided by P. Lunn, North 
Carolina State University) were then added and incubated for 1 hour at 37C. The plates were then 
                                                     
n Bio-Rad, Philadelphia, PA, USA. 
o MgBiologics, Ames, IO, USA.  
p Plasvacc USA Inc, Templeton, CA, USA. 
q Thermo Scientific, Rochester, NY, USA. 
r Sigma Aldrich, St. Louis, MO, USA. 
s Jackson ImmunoResearch, West Grove, PA, USA. 
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washed, and goat anti-mouse IgG-HRPi (1:2000 dilution) added for an additional hour at 37oC. 
Plates were washed between each step with PBST using an ELISA plate washer (MW 96/384)t. 
Substrate (3,3’,5,5’-tetra-methylbenzidine, peroxidase substrate)u was then added for 5 minutes. 
The reaction was stopped using stop solutionv. Absorbance was read at 450 nm using an ELISA 
plate reader w . Results from the sera samples were converted to ELISA units (EU) using a 
logarithmic trend line from the standard curve generated for total IgG and each subisotype143. A 
coefficient of determination (r2) of ≥ 0.90 for the standard curve was required for the results to be 
considered valid144.  
Foal evaluation and classification 
 Foals were observed daily by trained farm staff for increased respiratory rate or effort, 
mucoid or purulent nasal discharge, lethargy and anorexia. The farm veterinarian performed a 
complete physical examination at the time of sample collection, and at lung ultrasonography 
examination. All foals were screened with lung ultrasonography by the farm veterinarian at 30. In 
cases where ultrasonographic lung lesions compatible with R. equi142 were identified, serial lung 
ultrasonographic examinations (once a week) were performed for as long as the lung lesions were 
visualized. Foals negative for lung lesions at 30 days, and which remained clinically normal 
thereafter, were not subsequently subjected to additional ultrasonography. All physical and 
ultrasonographic findings were recorded and stored at the farm as medical records. 
 Each year, upon completion of sample collection, medical records were reviewed for the 
presence of specific signs of pneumonia including increased respiratory rate and effort, abnormal 
lung auscultation, purulent nasal discharge, spontaneous cough, tracheal rattle, submandibular 
and/or retropharyngeal lymph node enlargement, and lung lesions detected by ultrasonography. 
Foals were categorized as regressors based on the presence of ultrasonographic lesions indicative 
of rhodococcal pneumonia, which spontaneously resolved over time, without detection of clinical 
                                                     
t Bethyl Laboratories, Inc, Montgomery, TX 77356 USA 
u Beckman Coulter, Brea, CA, USA. 
v KPL, Gaithersburg, MD, USA. 
w Bio-Rad, Philadelphia, PA, USA. 
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signs of pneumonia or medical treatment. Based on the presence of one or more clinical sign(s) of 
lower respiratory infection in addition to ultrasonographic detection of lung lesions indicative of 
rhodococcal pneumonia, foals were categorized as progressors. Foals lacking ultrasonographic 
lesions indicative of rhodococcal pneumonia or specific clinical sign(s) of lower respiratory 
infection over the first 4 months of life, were categorized as no respiratory abnormalities (NRA).  
Statistical Analysis 
 Data were analyzed using a commercial software (SigmaPlot, SPSS Inc., Chicago, IL, 
USA). Variation of IgG titers, expressed as ELISA units (EU), among all HIP units and lots were 
assessed using coefficients of variation (CV%). Differences in IgG titers between HIP lots were 
assessed using Kruskal-Wallis one-way analysis of variance on ranks. Differences in IgG titers of 
the dam’s serum, the foal’s serum and the HIP samples grouped as progressors, regressors and 
NRAs were assessed using Kruskal-Wallis one-way analysis of variance on ranks. Multiple 
comparisons were performed using Dunn’s method. Shapiro-Wilk test was used to assess for data 
normality. Significance was set at p<0.05. 
 
Results 
 Fifty-five and 79 foals were initially enrolled in 2015 and 2016, respectively. However, 
only 122 foals had complete records and were further considered for data analysis. Overall, 30 foals 
were categorized as regressors, 13 as progressors, and 79 as NRAs. Twenty different HIP lots of 
the same product were used in the study. 
 Coefficients of variation determined for each IgG subisotype among all HIP samples and 
different lots are shown in Table 4.1.  
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Table 4. 1 Coefficients of variation (%) determined for VapA specific IgG subisotypes for all HIP 
samples (Overall) and different lots. N/A = coefficient of variation could not be calculated because 
there was only a single sample within the lot #.  
 
 There were significant differences in the median values of the total IgG (p = 0.025), IgGa 
(p <0.001), IgGb (p <0.001), and IgG(T) (p <0.001), between HIP lot numbers (Figs. 4.1-4).  
 
Lot# IGG	total IgGa IgGb IgG(T)
1 49.39 51.74 54.50 32.79
2 45.02 57.73 32.89 28.15
3 58.52 63.38 55.71 39.15
4 57.81 65.87 59.07 58.03
5 N/A N/A N/A N/A
6 39.18 55.54 46.33 47.53
7 60.43 61.40 59.22 58.09
8 70.83 91.88 79.37 31.83
9 51.96 56.79 71.16 52.33
10 N/A N/A N/A N/A
11 N/A N/A N/A N/A
12 0.44 0.24 0.35 0.34
13 0.52 0.47 0.40 2.48
14 0.38 0.25 0.27 0.26
15 0.56 0.62 0.33 0.09
16 0.51 0.46 0.44 0.71
17 0.28 0.22 0.30 0.51
18 0.21 0.46 0.56 0.10
19 0.48 0.27 0.29 0.23
20 0.38 0.41 0.30 0.51
Overall 0.53 0.85 0.75 3.84
Coefficient	of	Variation	(%)
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Figure 4. 1 Total VapA specific IgG concentration in 20 lots of HIP. The overall difference was 
significant (p=0.025). 
 
 
Figure 4. 2 VapA specific IgGa concentration in 20 lots of HIP. The overall difference was 
significant (p<0.001). 
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Figure 4. 3 VapA specific IgGb concentration in 20 lots of HIP HIP. The overall difference was 
significant (p<0.001). 
 
 
Figure 4. 4 VapA specific IgG(T) concentration in 20 lots of HIP. The overall difference was 
significant (p<0.001). 
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 There were no significant differences in the dam’s, HIP, or the foal’s VapA specific IgGa, 
IgGb, or IgG(T) between progressor, regressor and NRA foals. Total IgG was significantly 
different only in the HIP received by progressor, regressor and NRA foals. Regressor foals received 
HIP with significantly higher concentrations of total IgG than progressor (p=0.018), and NRA 
(p=0.026) foals (Fig. 4.5). When only progressor and regressor foals were compared, regressor 
foals received HIP with significantly higher concentrations of total IgG than progressor foals 
(p=0.012). (Fig. 4.6) 
 
 
Figure 4. 5 Total VapA specific IgG concentration in the HIP received by NRA, regressor and 
progressor foals. Asterisk denotes significant difference between the regressor and the other groups. 
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Figure 4. 6 Total VapA specific IgG concentration in the HIP received by regressor and progressor 
foals. Asterisk denotes significant difference between groups. 
 
Discussion 
 Consistent with previous reports146, we demonstrated that IgG varies greatly within and 
between different lots of the same HIP product. Indeed, our results show an even greater inter-lot 
variation (53 to 384%) than what was previously reported for the same product (17 to 123%). 
Although the amount of total IgG received by NRA and infected foals, i.e., progressor and regressor 
foals together, in HIP was not significantly different (data not shown), regressor foals received HIP 
with significantly greater amounts of total IgG than progressor foals (Fig. 4.6). This result suggests 
that marked variation in total IgG content may have had an impact on the clinical outcome of 
naturally exposed foals. 
Our results support a role of IgGs in alleviating severity of rhodococcal pneumonia since 
foals receiving more IgG were less severely affected. As demonstrated in vitro, opsonizing IgGs 
promote R. equi phagocytosis and killing162,163. VapA antibodies, in particular, have been shown to 
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be important in protecting adult horses164, foals165 and mice82 against rhodococcal disease. In 2016, 
a low-dose challenge study designed to closely mimic natural exposure, evaluated HIP efficacy and 
showed that treated foals were less severely affected with rhodococcal pneumonia118.   
Although regressor foals received significantly higher amounts of IgG than progressor 
foals, the present observational study does not prove a cause-effect relationship between these two 
variables. The possibility that R. equi-specific antibodies are not solely responsible for the observed 
results cannot be discounted. Other protective constituents of plasma might include fibronectin, 
interferon, cytokines, complement factors, and other proteins, several of which might aid in 
immunologic defenses166. Nevertheless, a recent study showed that foals given HIP or purified 
equine immunoglobulin specific for VapA and VapC had less severe pulmonary lesions and fewer 
R. equi in lungs than controls given saline82. Furthermore, disease outcomes observed in this study 
were likely influenced by individual cell-mediated mechanisms. 
The present observational study had inherent limitations that need to be taken into account 
when evaluating the results. All foals born at the farm received HIP, therefore no untreated foals 
were available to serve as controls. Consequently, the HIP efficacy in conferring protection against 
disease could not be determined. Also, the invasiveness, risks, costs and time associated with sterile 
trans-tracheal washes, precluded the use of this technique for definitive diagnosis of rhodococcal 
disease. Therefore, results should be interpreted based on the high positive predictive value of 
ultrasonographic detection of the characteristic R. equi lung lesions in foals from endemic farms107. 
Finally, some foals ultimately classified as NRAs may have had subclinical disease with undetected 
lung lesions, since only one lung ultrasonographic examination was performed at 30 days of age.    
 In conclusion, a great lack of uniformity in IgG content within and between different lots 
of a HIP product was detected. Furthermore, it is probable that this variation might have had an 
impact on disease outcome, as regressor foals received significantly greater amounts of IgG.  
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CHAPTER 5 
R. EQUI PILI-BASED VACCINE CANDIDATE FAILED TO CONFER PROTECTION TO 
FOALS AGAINST CHALLENGE 
 
Introduction 
Rhodococcus equi, a facultative intracellular and soil saprophytic bacteria, has worldwide 
distribution, and is considered one of the most important pathogens of early life in horses1. Alveolar 
macrophages are the primary survival and replication niche for R. equi18. In infected foals, a life-
threatening pyogranulomatous pneumonia develops within the first months of life2. The reasons for 
the unique susceptibility of young foals to this infection are not completely understood. In addition 
to the absence of immunological memory, neonates of most species have diminished innate 
immune responses, decreased antigen presenting cell function, and are less able to mount type-1 
immune responses51,167. Indeed, epidemiological evidence from field and challenge studies 
indicates that foals are most susceptible to rhodococcal infections shortly after birth21–24. Many 
endemically infected farms experience morbidity of 70% or greater, and case fatalities ranging from 
13% to 40% from R. equi pneumonia3–6. This disease has a major negative financial impact in the 
equine industry due to the ubiquitous pathogen distribution, high cumulative disease incidence in 
affected farms, and costly preventive and treatment measures.  
Current methods for control and prevention rely on highly sensitive but poorly specific 
screening techniques for early detection of pneumonia, and on administration of R. equi hyper 
immune plasma, which may only confer partial protection, and is cost-prohibitive in many 
occasions. Standard-of-care treatment of affected foals with antimicrobials consists of a 
combination of macrolide and rifampin, which may last for months, has important potential adverse 
effects, and is not consistently successful107. Furthermore, overtreatment of foals over the past 
decade has led to an alarming emergence of multi-drug resistant R. equi on different 
continents113,114, urging for efficient disease prevention rather than reliance on treatment.  
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Numerous attempts have been made to develop an effective vaccine for use in foals that is 
safe, immunogenic and efficacious. However, candidates based upon the traditional vaccine 
platforms such as live125, killed126,127 and attenuated128 have not been successful. Molecular based 
vaccines, such as DNA129,130, subunit131 and genetically attenuated132,133R. equi with theoretical 
potential have not conferred protection in mice. More recently, bacterial vector vaccines have 
shown positive results in murine models134–136, but not yet in foals.  
Notwithstanding failed attempts to actively immunize foals, evidence of a role of antibody 
in partial protection against R. equi infection14,82,123,165 suggests that vaccination of mares and 
subsequent passive transfer of immunity to foals via colostrum could confer some degree of 
protection. Initial unsuccessful attempts to prevent pneumonia by immunization of dams with 
inactivated or killed R. equi 120,168,169, may be explained by failure to include important virulence 
factors. Later research has established the role of the virulence-associated plasmid (pVAP) and its 
encoded factors as a critical determinant of R. equi pathogenicity 170–173. Although the mode of 
action of the Vap proteins in the host-pathogen interaction remains unkown, vaccination strategies 
involving passively acquired Vap-A immunoglobulins by foals via colostrum have been reported 
as encouragingly effective160,163.  
Sequencing of the R. equi 103+ genome has revealed potential virulence determinants, 
including the horizontal gene transfer island encoding cytoadhesive Flp type IVb subfamily pili16. 
The R. equi pili (Rpl) form long, rigid appendages, usually 2-5 per bacterial cell16, and mediate 
bacterial attachment to alveolar macrophages, a feature essential for lung colonization in mice9. 
Vaccination of mice with a synthetic Rpl peptide elicited full protection against experimental 
challenge (Jose Vazquez-Boland, personal communication). Unpublished in vitro studies have 
indicated that Rpl antibodies enhance alveolar macrophage bacterial uptake and killing (Jose 
Vazquez-Boland, personal communication). Furthermore, Rpl has been identified as immunogenic 
R. equi antigen, based on the detection of Rpl antibodies in foals with clinical rhodoccocal disease 
(Jose Vazquez-Boland, personal communication).  
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In this context, development of an effective vaccine would have immediate welfare and 
financial benefits worldwide. With this purpose, we hypothesized that Rpl antibodies passively 
acquired via colostrum of dams immunized with the Rpl antigen would protect foals against 
experimental infection of foals with Rhodococcus equi 103+.  
 
Materials and Methods 
Study Design  
Twenty-seven healthy, pregnant mares were included in this study. Approximately 2 
months prior to predicted foaling date, individual baseline serum Rpl antibody titers were 
determined by Rpl ELISA. Mares were initially grouped based on their predicted foaling week. 
Within each group, mares with the lowest Rpl antibody titers were assigned into the non-vaccinated 
or control group, while mares with the highest Rpl antibody titers were assigned into the vaccinated 
or treated group.  
 Based on preliminary data (not shown), each mare was vaccinated with two consecutive 
doses, given 6 and 4 weeks prior to predicted foaling date. Sterile saline (1 mL) was administered 
to the non-vaccinated group at the same time. Injection sites were monitored daily for local 
reactions for duration of the study. Serum samples were collected at 4 and 6 weeks post-
vaccination.  
Starting 10 days prior to predicted foaling date, each mare was checked twice daily for 
udder development and presence of colostrum. When colostrum was detected, 3-5 ml sample were 
collected and stored at -20oC. Only colostrum collected nearest to the approximate parturition time 
were assayed for Rpl antibody. 
All foals were born unattended and had free-access to colostrum. Within 48 hours post-
partum, a physical examination, lung ultrasonography, complete blood work and an IgG SNAP 
Test (IDEXX, Pharmaceuticals Inc.) were performed. Foals were included in the study if deemed 
clinically healthy, and without any significant clinical or ultrasonographic abnormalities, failure of 
passive transfer (IgG < 800 mg/dL) or blood work abnormalities. All foals were challenged at 3-7 
73 
 
days of age, and evaluated for the presence and severity of pneumonia for the following 8 weeks. 
Sera were collected immediately prior to challenge, as well as a sample of their bronchoalveolar 
lavage fluid (BALF) to determine its Rpl antibody concentrations. 
 
Vaccine (provided by Jose Vazquez-Boland’s group) 
 A 19-mer peptide, corresponding to the C-terminus of the Rpl protein, fused to GST 
protein was expressed in Escherichia coli (Fig. 1). Recombinant protein was purified by affinity 
chromatography. Antigen quality control included LPS quantification and culture to confirm 
sterility. Each vaccine dose included 300 μg of purified Rpl, as well as 120 μl of aqueous polymeric 
adjuvant with a profile similar to aluminum salt (MontanideTM Pet Gel, SEPPIC, France), in a final volume 
of 1 ml. Vaccine injections were administered intramuscularly, on alternating sides of the neck. 
 
 
 
 
 
 
 
 
 
 
 
Rpl ELISA – serum, colostrum and BALF samples (performed by Jose Vazquez-Boland’s group) 
An indirect enzyme-linked immunoassay (ELISA) was performed using streptavidin-
coated plates and a synthetic biotin-labeled pili peptide. Standard curves, positive and negative 
control serum samples were included on each plate. Standard curves were constructed with serial 
dilutions of a positive control serum. Sera from adult horses vaccinated with Rpl were used as 
Figure 5. 1 Overview of Rpl subunit recombinant vaccine production. 
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positive controls. Sera from the same horses collected prior to vaccination were used as negative 
controls. Rabbit anti-horse HRP IgG (ab6921, ABCAM, USA) was used as the conjugated 
secondary antibody. After addition of the substrate, absorbance was read using an ELISA plate 
reader. Results from the test sera were converted to ELISA units (EU) utilizing a logarithmic trend 
line from the standard curve143. A minimum coefficient of determination (r2) of ≥ 0.90 for the 
standard curve was determined for the results to be considered valid. 
 Serum, colostrum and BALF samples were assayed at a 1:100, 1:2000, and 1:1 dilution, 
respectively.  Colostrum from vaccinated mares, containing the lowest amounts of Rpl antibodies, 
were used as negative controls. Colostrum from vaccinated mares, containing the highest amounts 
of Rpl antibodies, were used as positive controls. Likewise, the BALF samples containing the 
lowest and highest amounts of Rpl antibodies were used as negative and positive controls, 
respectively.  
 
R. equi challenge  
A low-dose challenge study was performed with modifications of the previously described 
infection model24. R. equi 103+ was provided by Bioniche Animal Health. Bacteria were stored as 
a frozen stock in 20% glycerol and streaked onto a tryptic soy agar yeast extract (TSAYE) plate 
and incubated for 48 hours at 37°C. A single typical mucoid, creamy colony was selected from the 
plate, inoculated into tryptic soy yeast broth (TSBYE) and incubated for another 48 hours at 37°C. 
Bacterial concentrations were initially estimated based on optical density (OD) at 600nm 
wavelength and confirmed by serial dilution plating. All isolates were tested for the presence of 
VapA-carrying plasmid using PCR at the UKVDL. Agar plates were held at room temperature for 
an additional 72 hours at which time colony morphology was evaluated. Culture media were 
serially diluted using sterile PBS to obtain a total concentration of bacteria of 104 cfu/ml. One ml 
of 104 cfu/ml was used to inoculate each foal. The inocula were refrigerated during transportation 
to the farm, and until challenge was performed. An additional sample of inoculum taken to the 
farm, was later plated on TSAYE in the laboratory, to confirm bacterial viability and concentration. 
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 Foals were challenged at 3-7 days of age if adequate passive transfer had been documented, 
were deemed clinically healthy based on a normal complete blood cell (CBC) count, fibrinogen 
and thoracic ultrasonography. Prior to challenge, mare and foals were brought into stalls and the 
foals were sedated using a combination of valium (0.2 mg/kg) and butorphanol (0.05 mg/kg). A 
flexible tube was used to deliver the bacteria to the mid trachea (intratracheal instillation).  
 
Foal assessment 
After challenge, mare and foal returned to pasture and were evaluated for the following 8 
weeks. Foals were observed daily for increased respiratory rate or effort, mucoid or purulent nasal 
discharge, lethargy and anorexia. Rectal temperature was recorded twice a day. A complete 
physical examination was performed twice a week to detect signs of pneumonia including increased 
respiratory rate and effort, abnormal lung auscultation, purulent nasal discharge, spontaneous 
cough, and submandibular and/or retropharyngeal lymph node enlargement. In order to objectively 
assess respiratory disease severity, a scoring system was designed (Table 2.1).  
Bilateral lung ultrasonography was performed on all foals prior to, and biweekly after 
challenge using a 7.5MHz linear probe (CTS-7700V-SIUI, Universal Medical System Inc., 
Bedford Hills, NY). Lungs were scored based on the sum of the maximum diameters of each lesion, 
and a total score was obtained by adding both lung scores. All physical and ultrasound examinations 
were performed by the author.   
 Total white blood cell counts and fibrinogen were obtained once a week. Sample collection 
was discontinued if treatment for rhodococcal pneumonia was perceived as necessary based on the 
development of significant clinical signs of pneumonia, accompanied or not by fever. 
Confirmation of R. equi pneumonia was obtained either by performing an in vivo trans-
tracheal wash 4 weeks after challenge, or by post-mortem evaluation. Five randomly selected 
vaccinated foals and five age-matched non-vaccinated control foals were euthanized. All 
necropsies were performed by a board certified pathologist at the UKVDL, blinded to treatment. 
The lungs of each animal were separated, and each lung lobe weighed. The percentage of lung 
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tissue showing pleural and parenchymal lesions consistent with disease due to R. equi (% of 
affected lung parenchyma) was determined as previously described175. Gross lung lesion scores 
were generated based on the percentage of pneumonic lung on the pleural surface (abscess scores) 
using digital images with a grid. Sterile samples of approximately 100 mg collected from 3 pre-
determined sites within each lung (Acr, Dorso-medial, and DDB), right and left lung lymph nodes, 
as well as from a tracheal lymph node, were homogenized and serially diluted in phosphate buffer 
before plated on TSYEA (R. equi growth form lung homogenates). Lung tissue and 
tracheobronchial lymph nodes were also collected for bacteriological culture and histopathology. 
Carcasses were evaluated for signs of extrapulmonary lesions. 
 
Outcome evaluation 
Vaccine efficacy was evaluated comparing disease incidence and disease severity between 
vaccinated and control groups. Disease incidence was determined based on the presence of 
characteristic lung lesions detected on ultrasonography. Disease severity was assessed based 
physical examination scores, lung ultrasonography scores, clinical pathology data, and post-
mortem evaluations of the affected lungs.  
 
Statistical Analysis 
Concentrations of Rpl immunoglobulins in sera from vaccinated and control mares were 
compared overtime using two-way repeated measures analysis of variance (ANOVA).  Colostrum, 
BALF and sera, were evaluated using independent measures, t-test for differences in their 
concentrations of Rpl immunoglobulins between groups. Pearson’s correlation was used to test for 
association between concentration of Rpl IgG in sera from mares and foals, mare’s colostrum and 
foal’s BALF. 
Differences in physical examination, ultrasonographic and abscess scores between foals of 
vaccinated and non-vaccinated mares were evaluated using the Holm-Sidak method. Differences 
in white blood cell count and fibrinogen concentrations over time and between groups were 
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evaluated using two-way repeated measures ANOVA. Percentages of affected lung parenchyma 
and R. equi posititve culture from lung homogenates (cfu counts) were compared between groups 
using independent measures, t-test.  
For all analyses, data normality and equal variance were tested using Shapiro-Wilk and 
Brown-Forsythe tests, respectively. Significance was set at P<0.05. 
 
Results 
Fourteen mares were included in the vaccination group and 13 mares served as negative 
controls (Fig. 5.2). 
 
  
Figure 5. 2 Baseline serum Rpl specific IgG titers of pregnant mares approximately 2 months prior 
to foaling. Each bar represents a control (blue) and a vaccinated (red) mare ranked from lowest to 
highest antibody titer.  
 
No significant difference in pre-existing Rpl titers between the vaccinated and control 
mares (p = 0.689) was detected.  However, a significant increase in Rpl specific IgG was observed 
in vaccinated mares at 4 (p <0.001) and 6 (p <0.001) weeks. Significant differences were observed 
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between groups at 4 (p<0.050) and 6 (p<0.050) weeks post-vaccination, when vaccinated mares 
had significantly higher concentrations of Rpl specific IgG (Fig. 5.3).  
 
 
Figure 5. 3 Vaccinated and control mare’s Rpl specific IgG titers over time. Asterisk indicates 
significant difference from baseline. Letter “a” indicates significant difference between groups. 
 
Colostrum of vaccinated mares had significantly higher concentrations of Rpl specific 
IgG compared to controls (p<0.001) (Fig. 5.4). 
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Figure 5. 4 Titers of Rpl specific IgG in colostrum of control and vaccinated mares. Asterisk 
indicates significant difference between groups.  
 
Significantly higher concentrations of Rpl specific IgG were found in the sera of foals of 
vaccinated mares at 3-7 days of age (p<0.001) (Fig. 5.5), and in their BALF (p= 0.006) (Fig. 5.6), 
compared to foals of control mares.  
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Figure 5. 5 Rpl specific IgG serum titers of foals of control and vaccinated mares 3-7 days after 
being born (before experimental infection). Asterisk indicates significant difference between 
groups.  
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Figure 5. 6 Rpl specific IgG BALF titers of foals of control and vaccinated mares 3-7 days after 
being born (before experimental infection). Asterisk indicates significant difference between 
groups.  
 
 There were positive significant correlations between the mare’s anti-Rpl titers at 4 weeks 
post-vaccination, the foal’s serum anti-Rpl titers and the foal’s BALF samples (Table 5.1). 
 
 
Table 5. 1 Pearson correlation coefficient and p values between the Rpl specific IgG titers of mares 
and foal’s serum, mare’s colostrum and foal’s BALF . 
 
There was no difference in lung disease incidence among the foals born from vaccinated 
and control mares, as all foals in the vaccine group developed lung lesions detected 
Colostrum Foal's	Serum Foal's	BALF
Mare's	4w	post-vaccine 0.208 0.507 0.424 Pearson	Correlation	Coefficient
0.298 0.00699 0.0275 P	value
Colostrum 0.22 0.259 Pearson	Correlation	Coefficient
0.271 0.192 P	value
Foal's	Serum 0.596 Pearson	Correlation	Coefficient
0.00103 P	value
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ultrasonographically while only one foal in the control group did not develop lung lesions that could 
be detected ultrasonographically (Table 5.2). 
 
Table 5. 2 Ultrasound scores of all foals of control and vaccinated mares before and after challenge, 
at different examination times (1-16).  ε indicates euthanasia.  
  
There were no significant differences in physical examination scores (p=0.227) (Table 5.3), 
lung ultrasonography scores (p=0.986), abscess scores (p=0.310), % affected lung parenchyma 
(p=0.548), R. equi growth from lung homogenate (p=0.690) (Table 5.4), white blood cells counts 
(p=0.264) (Table 5.5), and fibrinogen (p=0.336) (Table 5.6) between foals born from vaccinated 
and control mares.  
Foal Group Pre-challenge 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16
Q1 Control 0 0 0 0 0.4 0.4 1.1 1.4 0.7 0.2 0.3 0.2 0 0 0 0 0
Q7 Control 0 0 0 0 0 0 0 0 0 0 0 0 7.1 ε
Q8 Control 0 0 0 0 0.3 0.6 11 35.1 38.1 ε
Q12 Control 0 0 0 0 0 0 0 0 1.6 ε
Q13 Control 0 0 0 0 0 0 1.3 4 5.8 6.1 1.3 0.4 0.6 0 0 ε
Q15 Control 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Q17 Control 0 0 0 0 1.1 0 0 0 1.7 0.9 0 0 0 0 0 0 0
Q18 Control 0 0 0 0 0 0 0.2 3 3.2 0.8 0.5 0 0 0 0.3 0.3 0
Q19 Control 0 0 0 0 0 0 0 0 0 0 13.2 5.5 0.7 0.8 0.3 0 0.7
Q20 Control 0 0 0 0 0 1.9 4.3 4.2 0.2 0 0.8 3.4 3.7 3.4 0 0 0
Q21 Control 0 0 0 0 1.8 20.9 11.1 13 2.4 1 0.9 0.4 0.6 0 0 0 0
Q23 Control 0 0 0 0 0 0.6 3.2 8.2 7.7 4.2 3.7 0.4 1.8 ε
Q29 Control 0 0 0 0 0 0 0 16.1 3.5 0.9 0 0 0 0 0 0 0
Q2 Vaccinated 0 0 0 0 0.5 1.3 3.3 3.6 13.9 21.1 10.3 3.9 2.3 2 1.8 ε
Q4 Vaccinated 0 0 0 0 0.9 5.7 3.4 1.4 0.8 1.7 0.4 0 0.4 0.5 0.5 0 0
Q5 Vaccinated 0 0 0 0 0 0.7 0 0 0 0.3 0 0 0 ε
Q6 Vaccinated 0 0 0 0 0 4.5 11.3 9.4 0.9 2.5 0.8 0 0.9 1.1 0.4 0 0
Q9 Vaccinated 0 0 0 0 5.3 13 5 3.6 6.5 4.7 2 2 1.3 0 0 0 0
Q10 Vaccinated 0 0 0 0 0.2 1 0 1.1 8 ε
Q11 Vaccinated 0 0 0 0 0 1.6 1.6 4.2 4 3.7 1.1 0.8 0 0 0 0.4 0.3
Q14 Vaccinated 0 0 0 0 0.3 0.9 3.2 0.8 0 0 0 0 0 0 0 0 0
Q16 Vaccinated 0 0 0 0 0.4 0 0.8 2.9 15.7 ε
Q22 Vaccinated 0 0 0 0 0 0 1 7.5 5.2 15.4 20.8 12.2 3.9 ε
Q25 Vaccinated 0 0 0 0 0 0 0 0 0 0 0 3.8 4 4.2 3.2 2.2 0
Q26 Vaccinated 0 0 0 0 0 0 0 0.6 0.5 0.5 0 0.2 0 0 0 0 0
Q27 Vaccinated 0 0 0 0 0 0 1.4 4.8 12.3 7.5 2 1.9 1 0 0 0 0
Q28 Vaccinated 0 0 0 0 0.5 1 0 0 0 0 0 0 0 0 0 0 0
Ultrasound	scores	of	foals	born	from	vaccinated	and	control	mares
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Table 5. 3 Physical examination scores of all foals of control and vaccinated mares before and after 
challenge, at different examination times (1-16).  ε indicates euthanasia. 
 
  
Table 5. 4 Post-mortem parameters of foals of vaccinated and control mares. 
 
Foal Group Pre-challenge 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16
Q1 Control 0 0 0 0 0 0 0 2 0 0 0 0 0 0 0 0 0
Q7 Control 0 0 0 0 0 0 0 0 0 0 0 0 0 ε
Q8 Control 0 0 0 0 0 0 1 5 9 ε
Q12 Control 0 0 0 0 0 0 0 0 0 ε
Q13 Control 0 0 0 0 0 2 0 0 0 2 0 1 0 0 0 ε
Q15 Control 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Q17 Control 0 0 0 0 2 0 0 0 0 1 2 2 2 0 2 1 0
Q18 Control 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Q19 Control 0 0 0 0 0 0 0 0 0 0 5 7 4 1 0 1 2
Q20 Control 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Q21 Control 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0
Q23 Control 0 0 0 0 0 0 0 0 0 0 0 0 0 ε
Q29 Control 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Q2 Vaccinated 0 0 0 0 0 1 0 0 1 2 2 0 0 0 0 ε
Q4 Vaccinated 0 0 0 0 0 1 1 0 0 0 0 0 0 0 0 0 0
Q5 Vaccinated 0 0 0 2 0 0 0 0 0 0 0 0 0 ε
Q6 Vaccinated 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1
Q9 Vaccinated 0 0 0 0 0 0 2 0 0 0 0 0 0 0 0 0 0
Q10 Vaccinated 0 0 0 0 0 0 0 0 0 ε
Q11 Vaccinated 0 0 0 0 0 0 0 2 0 2 0 0 0 0 0 0 0
Q14 Vaccinated 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0
Q16 Vaccinated 0 0 0 0 0 0 0 0 2 ε
Q22 Vaccinated 0 0 0 0 1 0 0 0 0 3 2 2 1 ε
Q25 Vaccinated 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Q26 Vaccinated 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Q27 Vaccinated 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Q28 Vaccinated 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Physical	examination	scores	of	foals	born	from	vaccinated	and	control	mares
Foal Group %	total	lung	parenchyma	affectedAbscess	Score R.	equi	culture	(cfu/mg)
Q07 Control 0.3 0 3.8
Q08 Control 26.57 26 10.4
Q12 Control 7.88 5 959.0
Q13 Control 0.83 1 6.6
Q23 Control 0.39 0 3.2
Q02 Vaccinated 4.09 4 0.0
Q05 Vaccinated 0.4 1 201.6
Q10 Vaccinated 8.15 6 11.4
Q16 Vaccinated 11.88 12 965.2
Q22 Vaccinated 5.44 7 4.2
Post-mortem	parameters	of	foals	born	from	vaccinated	and	control	mares
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Table 5. 5 White blood cell count of all foals of control and vaccinated mares before and after 
challenge, at different examination times (1-8).  ε indicates euthanasia. 
 
 
Table 5.6 Fibrinogen of all foals of control and vaccinated mares before and after challenge, at 
different examination times (1-8). ε indicates euthanasia. 
Foal Group Pre-challenge 1 2 3 4 5 6 7 8
Q1 Control 12.3 11.1 5.6 14.5 12 8.9 11.3 12.9 10.8
Q7 Control 8.1 6.8 7.5 8.3 12.3 11.2 12.8 ε
Q8 Control 9.4 13.8 12.3 11.7 14.1 ε
Q12 Control 9.2 10.1 13.9 12.7 11.4 ε
Q13 Control 11.9 10.3 9.7 9 14.9 15 15.4 13.4 ε
Q15 Control 7.2 6.5 7 7.3 7.8 6.7 12.6 10.3 12.9
Q17 Control 9.6 7.7 14 11.1 15.2 13.7 15 15.4 14.5
Q18 Control 10.5 14.8 9.7 9.6 11.5 15.6 10 11.7 7.4
Q19 Control 12.5 12 10.2 7.3 10.3 11.4 14.8 12 17.3
Q20 Control 8.6 12.2 9.6 8.9 9.2 10.2 13 9.9 9.2
Q21 Control 8.1 8.4 10.1 12.6 13.5 13.5 14.7 17.2 17.6
Q23 Control 9 17.8 6.5 11.1 16 19.2 12.3 ε
Q29 Control 9 10.7 7.3 11.7 12.2 9.3 10.8 10.9 9.8
Q2 Vaccinated 9.7 8.9 20.9 14.4 18.8 8.3 9.2 18.8 ε
Q4 Vaccinated 11.4 13.6 11.7 12.1 13.8 10.6 7.7 11.3 15.4
Q5 Vaccinated 7.8 8.3 11 9.2 11.4 9.6 11.3 ε
Q6 Vaccinated 7.9 11.1 10.7 9.8 10.7 7.9 12.3 6.6 15.5
Q9 Vaccinated 10.8 10 8.8 12 14.1 10.4 9 10.7 11.2
Q10 Vaccinated 7 7.8 9.6 9 9 ε
Q11 Vaccinated 9.4 8.7 16.9 6.4 7.6 6.9 9.9 10 9.9
Q14 Vaccinated 7.2 8.7 10.9 9.7 10.9 10.3 8.8 8 10.3
Q16 Vaccinated 10.4 11.6 17.1 12.9 11.3 ε
Q22 Vaccinated 9.3 7.5 10.6 9.6 6.8 24.3 8.5 ε
Q25 Vaccinated 9 20.9 35.8 18.6 14.9 11.6 16 16.5 15
Q26 Vaccinated 6.5 10.8 9.5 7.3 12 6.7 18.9 11.4 10.2
Q27 Vaccinated 7.3 9.1 9.8 6.9 8 12.5 13.1 11 11.3
Q28 Vaccinated 7.8 7.7 8.9 12.3 13.8 10.7 13.2 11.2 12
White	blood	cell	(WBC)	count	of	foals	born	from	vaccinated	and	control	mares
Foal Group Pre-challenge 1 2 3 4 5 6 7 8
Q1 Control 280 279 533 359 337 303 322 535 577
Q7 Control 268 312 345 400 422 394 337 ε
Q8 Control 288 256 314 465 613 ε
Q12 Control 314 596 636 404 357 ε
Q13 Control 259 302 358 594 504 467 364 368 ε
Q15 Control 323 374 336 329 321 462 451 380 344
Q17 Control 316 389 309 310 405 410 353 300 326
Q18 Control 319 389 309 310 405 410 353 300 326
Q19 Control 322 483 571 611 839 1053 982 889 607
Q20 Control 316 453 425 375 389 352 365 336 338
Q21 Control 296 359 409 367 654 631 546 545 500
Q23 Control 347 695 808 402 864 708 794 ε
Q29 Control 270 360 365 362 382 337 314 375 9.8
Q2 Vaccinated 283 407 332 331 353 424 336 310 ε
Q4 Vaccinated 403 358 461 464 423 391 369 375 419
Q5 Vaccinated 236 269 304 280 276 268 310 ε
Q6 Vaccinated 227 280 319 368 410 509 343 554 594
Q9 Vaccinated 436 453 392 614 453 479 429 427 457
Q10 Vaccinated 412 472 668 413 396 ε
Q11 Vaccinated 403 326 392 379 383 394 346 342 328
Q14 Vaccinated 267 219 396 371 275 296 319 290 285
Q16 Vaccinated 421 638 733 765 682 ε
Q22 Vaccinated 264 377 639 556 718 720 726 ε
Q25 Vaccinated 277 857 1070 769 546 532 564 396 402
Q26 Vaccinated 224 257 355 416 423 503 560 303 354
Q27 Vaccinated 263 344 340 350 509 474 345 379 320
Q28 Vaccinated 274 296 370 397 418 490 486 603 510
Fibrinogen	of	foals	born	from	vaccinated	and	control	mares
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Discussion 
 The results demonstrated that the Rpl vaccine candidate induced an anamnestic response 
in vaccinated pregnant mares, and the Rpl antibodies concentrated in the colostrum. Furthermore, 
foals that ingested colostrum from vaccinated mares had significantly higher serum titers of Rpl 
specific IgG and in BALF compared to foals of non-vaccinated mares. However, passively acquired 
Rpl specific IgG of foals in the vaccine group did not confer protection against rhodococcal 
pneumonia, nor decrease disease severity after challenge compared to control foals.  
Virulent R. equi survives and replicate within alveolar macrophages11,176. Vaccination 
against intracellular pathogens is usually focused on generation of cell-mediated immune responses 
in the host, where a pool of memory T-cells is induced and is able to mediate either killing of the 
infected cell or induce killing mechanisms in the infected cell177. In contrast, the Rpl vaccine 
composed of a synthetic peptide with an alum-like adjuvant was expected to mostly induce a 
humoral response that could be passively transferred via colostrum. Because the R. equi pilus has 
been shown to mediate bacterial attachment to host cells (JBV, personal communication), passive 
transfer of Rpl specific IgG was expected to opsonize and, therefore, prevent or decrease 
intracellular infection by R. equi. This would result in a lack of, or fewer lung lesions in the foals 
of vaccinated mares.  
Mares were vaccinated at 4 and 6 weeks prior to their predicted foaling date to induce a 
peak antibody response during the last 15 days of gestation. It is during this time that the non-
selective secretion of serum immunoglobulins into colostrum occurs178. Indeed, our results indicate 
that the antibody peak response in vaccinated mares likely occurred shortly before or at parturition 
(Fig. 5.4). The results also indicate that induced Rpl specific IgG was present in the colostrum from 
vaccinated mares (Fig. 5.5), as well as transferred to their foal’s serum and BALF (Figs. 5.6 and 
5.7). Interestingly, significant positive correlations were observed between the Rpl specific IgG 
titer in the mare and foal’s sera, and foal’s BALF, indicating specific immunoglobulins exit 
systemic circulation after oral uptake and become compartmentalized. A lack of association 
between titers in mare and foal’s sera, and foal’s BALF and colostral titers may be explained by 
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the suboptimal timing of colostrum collection. Since parturition was unattended, a colostrum 
sample collected immediately post-partum and before suckling was not possible. Marked decline 
in immunoglobulin concentrations in the equine colostrum after suckling has occurred has been 
described178 For that reason, we chose to analyze the colostrum collected up to 12 hours prior to 
parturition. It is possible that colostrum samples collected from immediate post-partum and prior 
to suckling would have shown different results. Nonetheless, systemic and local Rpl specific IgG 
present in sera and BALF of foals of vaccinated mares, did not protect against experimental 
challenge.  
Previous failures of peptide vaccines have been attributed to use of single peptide epitopes 
as vaccine candidates, immune evasion mechanisms, failure to elicit a controlled and prolonged 
immune responses, and inappropriate design of clinical trials179. The Rpl vaccine was formulated 
to induce an immune response against a linear epitope, while the vast majority of antigen-antibody 
interactions involve binding to conformational epitopes180. An antigen epitope-antibody mismatch 
could explain the lack of vaccine efficacy. However, it is since the same antibody was fully 
protective against R. equi challenge in mice (JBV, personal communication).  
Earlier studies that evaluated active immunization of mares with killed or inactivated R. 
equi with subsequent colostral transfer of immunity to foals failed in preventing foals from 
developing R. equi pneumonia120,169. These studies were performed before Takai et al., 
demonstrated the importance of live, virulent R. equi in eliciting a protective immune response in 
mice181. Most recently, promising results were observed after the immunization of a small number 
of pregnant mares with a water-based nanoparticle adjuvanted (IMS 3012) VapA protein163.  
Vaccinated mares had higher serum IgG and opsonic activity, which was transferred to foals, 
compared to mares vaccinated with killed whole cell R. equi. Likewise, Becu et al., reported a 
significant reduction in R. equi related foal mortality when pregnant mares were vaccinated with 
soluble R. equi antigens, including VapA160. While protective responses were observed, a great 
variation in the humoral response produced by vaccinated mares was also reported160. Indeed, the 
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antibody production of vaccinated mares in the present study varied considerably, and cannot be 
excluded as a reason for vaccine failure.  
Since vaccination of mares has not been consistently effective in preventing rhodococcal 
pneumonia in foals, attention has been redirected toward actively vaccinating foals. Vaccines 
centered on DNA technology have been shown to be effective in inducing desirable Th1 responses 
in mice129,130,182 However, most of these vaccines did not protect against R. equi infection in mice. 
Therefore, additional work is needed to optimize the DNA technology for neonatal foals. Live, oral 
vaccines containing virulent R. equi have shown positive results when administered to 
foals117,127,134. Thus, the impact and significance of a live oral vaccine on the gastrointestinal tract 
of foals, fecal shedding and subsequent on-farm contamination need to be established to satisfy 
safety considerations. In agreement with the results of the present study, previous Vap-peptide 
vaccines have been shown to induce a Vap-specific immunoglobulin production, with a mixed Th1 
and Th2 profile in mice, adult horses and neonatal foals81,153. Protection elicited by these Vap-
peptide vaccine candidates has not been reported in foals.    
Induction of effective immune responses through vaccination requires both humoral and 
cell-mediated immune responses. Dose, antigen type, route of administration, and adjuvant type 
are central considerations. Combination of a modified live attenuated oral vaccine with an adjuvant 
capable of stimulating a mixed Th1/Th2 response, with less potential to contaminate the 
environment, may be a promising vaccine strategy. Nevertheless, there is the difficult challenge of 
eliciting a protective response in immunologically immature foal exposed to R. equi within the first 
few days of life.   
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CHAPTER 6 
CONCLUSIONS AND FUTURE DIRECTIONS  
 
 Although R. equi was first isolated from a horse almost 100 years ago, it remains a leading 
cause of mortality in foals. Sequence analysis of the R. equi 103+ genome, has yielded a better 
understanding of the pathogen’s biology yet much remains unknown to explain the foal’s unique 
susceptibility. In addition, lack of early diagnostic and prophylactic methods are a major frustration 
to the field veterinarian. 
Development of a diagnostic tool to precisely identify foals at risk of becoming clinically 
affected by R. equi, and that would benefit from medical intervention would have an immediate 
positive impact on the horse industry. Early diagnosis of R. equi infection of the respiratory tract 
currently relies on screening techniques that are highly sensitive, although poorly specific resulting 
in widespread antimicrobial use. Based on the challenge model previously developed, IgG(T) was 
identified as a marker of infection. Unfortunately, when evaluated as a marker for clinical disease 
IgG(T) was not a reliable predictor of disease outcome following experimental challenge or natural 
infection. However, the possibility of using IgG(T) as a disease marker has not been exhausted yet. 
Only recently, the full complement of the horse immunoglobulin heavy chain constant regions 
genes was described. IgG(T) was then reassigned as IgG3 and IgG5. Additional research will be 
needed to assess these IgG(T) subisotypes as predictors of disease outcome once specific antibodies 
become commercially available.  
Comparison of the whole blood cytokine expression profiles of progressor and regressor 
foals was performed to provide a reliable, easy-to-perfom R. equi diagnostic test. However, it did 
not reveal differences in cell markers or cytokine mRNA expression of value in differentitation 
progressor from regressor foals. Nonetheless, it was only a first step taken towards identifying 
potential mRNA expression patterns that may differ among foals that are susceptible to R. equi, 
and foals that mount an effective immune response. Cytokine expression profiles of specific cell 
populations, such as PBMCs or alveolar macrophages, should be evaluated.  
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This study further evaluated the variability of IgGs among units of a commercially 
available HIP, and showed that naturally infected foals remaining free of clinical disease had 
received greater concentrations of total IgG. Observational data from a large number of foals 
collected over a period of 2 years is likely to weigh in future decisions of horse owners, farm 
managers, and field veterinarians regarding the use of HIP. 
Despite the lack of protection by the Rpl vaccine candidate reported here, the results 
emphasize the need of a more thorough approach when formulation vaccine antigens, as well as 
the importance of a cell-mediated immune response in addition to specific antibodies in order to 
obtain a protective immune response against R. equi.  
Although several limitations were identified throughout this body of work, some 
significant contributions towards improving current R. equi diagnostic and preventive measures 
were still achieved. For the first time, the humoral immune response and the whole blood cytokine 
and cell marker expression profiles of progressor and regressor foals were characterized either after 
challenge or natural infection. Evidence favoring the use of HIP in the field was provided. Finally, 
suscessful collaborative research involving different academic institutes, local field veterinarians 
and horse farms was accomplished.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
90 
 
APPENDIX 
Supplemental table A.1: VAPA ELISA results of challenged foals during the years 2016 and 2017 
before and 2, 4, 6 and 8 weeks post-challenge. 
 
Subject Group Time point Total IgG IgGa IgGb IgGt 
2 Progressor Pre-challenge 0.50 1.13 1.49 1.19 
2 Progressor 2w PC 0.48 1.14 1.65 1.44 
2 Progressor 4w PC 0.53 2.59 1.76 2.13 
2 Progressor 6w PC 1.62 7.27 3.28 147884.8 
2 Progressor 8w PC     
8 Progressor Pre-challenge 0.57 0.91 1.76 1.21 
8 Progressor 2w PC 0.54 1.05 1.85 1.46 
8 Progressor 4w PC 2.92 60.17 3.87 11.36 
8 Progressor 6w PC     
8 Progressor 8w PC     
11 Progressor Pre-challenge 2.63 1.24 2.40 1.39 
11 Progressor 2w PC 0.81 1.60 2.22 1.65 
11 Progressor 4w PC 1.09 6.21 2.33 1.37 
11 Progressor 6w PC 1.05 3.48 2.27 1.47 
11 Progressor 8w PC 1.73 4.38 3.98 2.21 
13 Progressor Pre-challenge 0.90 1.28 2.11 1.27 
13 Progressor 2w PC 0.68 1.40 2.10 1.46 
13 Progressor 4w PC 1.06 5.13 2.12 14.21 
13 Progressor 6w PC 1.58 7.48 3.04 42.95 
13 Progressor 8w PC     
17 Progressor Pre-challenge 1.66 1.92 3.91 1.21 
17 Progressor 2w PC 1.01 1.59 3.10 1.49 
17 Progressor 4w PC 3.20 5.62 4.29 2.99 
17 Progressor 6w PC 3.20 6.38 7.48 19.03 
17 Progressor 8w PC 4.56 8.29 9.53 60.76 
19 Progressor Pre-challenge 0.65 1.01 1.90 1.18 
19 Progressor 2w PC 0.66 1.09 1.85 1.18 
19 Progressor 4w PC 0.84 2.32 2.22 1.20 
19 Progressor 6w PC 1.92 5.16 4.32 1.32 
19 Progressor 8w PC 8.60 30.77 22.55 475.89 
22 Progressor Pre-challenge 0.52 0.92 1.56 1.23 
22 Progressor 2w PC 0.61 1.11 1.67 1.22 
22 Progressor 4w PC 9.03 93.81 13.37 6.10 
22 Progressor 6w PC 14.69 83.44 31.86 4879.66 
22 Progressor 8w PC     
R8 Progressor Pre-challenge 0.48 1.15 1.60 1.42 
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R8 Progressor 2w PC 0.48 1.11 1.57 1.36 
R8 Progressor 4w PC 1.40 5.73 2.81 1.60 
R8 Progressor 6w PC 24.33 538.37 45.66 167.62 
R8 Progressor 8w PC 26.77 434.89 44.67 66.03 
R10 Progressor Pre-challenge 2.08 2.57 4.54 1.39 
R10 Progressor 2w PC 1.24 1.97 3.22 1.41 
R10 Progressor 4w PC 1.82 35.81 4.53 24.51 
R10 Progressor 6w PC 4.79 48.25 11.33 443.74 
R10 Progressor 8w PC 5.77 29.10 10.91 569.00 
R13 Progressor Pre-challenge 1.42 2.10 3.16 1.45 
R13 Progressor 2w PC 1.01 1.76 2.61 1.42 
R13 Progressor 4w PC 1.26 7.21 2.77 2.82 
R13 Progressor 6w PC 1.69 4.21 3.62 4.27 
R13 Progressor 8w PC     
R14 Progressor Pre-challenge 0.60 1.67 1.78 1.45 
R14 Progressor 2w PC 0.53 1.38 1.70 1.45 
R14 Progressor 4w PC 1.83 15.52 2.47 16.33 
R14 Progressor 6w PC 4.49 45.78 6.18 1511.63 
R14 Progressor 8w PC 6.12 62.41 7.41 3797.02 
R18 Progressor Pre-challenge 0.85 1.44 2.24 1.40 
R18 Progressor 2w PC 0.59 1.38 1.82 1.44 
R18 Progressor 4w PC 1.29 5.14 2.28 2.49 
R18 Progressor 6w PC 3.77 25.58 6.94 5.40 
R18 Progressor 8w PC 5.70 40.02 10.65 7.40 
1 Regressor Pre-challenge 0.53 0.89 1.60 1.19 
1 Regressor 2w PC 0.50 1.01 1.73 1.45 
1 Regressor 4w PC 0.95 2.92 2.36 1.60 
1 Regressor 6w PC 1.63 6.07 4.02 42.15 
1 Regressor 8w PC 1.73 4.59 4.05 45.16 
4 Regressor Pre-challenge 0.64 1.31 1.73 1.21 
4 Regressor 2w PC 1.46 1.25 1.81 1.46 
4 Regressor 4w PC 0.60 3.45 1.87 1.96 
4 Regressor 6w PC 1.08 7.46 2.35 40.54 
4 Regressor 8w PC 2.34 25.56 4.73 1605.36 
5 Regressor Pre-challenge 1.26 6.79 2.25 1.23 
5 Regressor 2w PC 1.45 2.84 2.07 1.45 
5 Regressor 4w PC 0.92 4.07 2.75 3.23 
5 Regressor 6w PC     
5 Regressor 8w PC     
6 Regressor Pre-challenge 0.55 1.04 1.59 1.17 
6 Regressor 2w PC 1.49 1.55 1.73 1.49 
6 Regressor 4w PC 2.30 17.45 3.96 24576.13 
6 Regressor 6w PC 2.05 12.67 5.65 3411.15 
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6 Regressor 8w PC 1.98 4.91 3.47 67.25 
9 Regressor Pre-challenge 1.51 2.01 2.93 1.18 
9 Regressor 2w PC 0.87 1.50 2.47 1.46 
9 Regressor 4w PC 2.26 11.62 4.42 3.24 
9 Regressor 6w PC 8.62 41.48 14.13 13.70 
9 Regressor 8w PC 6.25 39.85 19.31 22.95 
14 Regressor Pre-challenge 6.48 5.57 6.91 1.23 
14 Regressor 2w PC 2.47 3.65 6.31 1.52 
14 Regressor 4w PC 1.79 3.08 3.54 1.80 
14 Regressor 6w PC 1.14 2.35 2.74 2.00 
14 Regressor 8w PC 1.05 1.85 2.63 2.19 
18 Regressor Pre-challenge 2.17 3.36 4.57 1.19 
18 Regressor 2w PC 1.55 2.18 3.69 1.46 
18 Regressor 4w PC 0.96 2.14 2.78 1.38 
18 Regressor 6w PC 0.96 1.84 2.22 2.34 
18 Regressor 8w PC 0.78 1.65 2.27 2.61 
20 Regressor Pre-challenge 1.21 1.27 2.39 1.22 
20 Regressor 2w PC 0.86 1.21 2.23 1.18 
20 Regressor 4w PC 1.34 4.96 3.20 2.61 
20 Regressor 6w PC 3.38 18.48 11.17 237.63 
20 Regressor 8w PC 8.60 21.40 21.62 7130.10 
23 Regressor Pre-challenge 0.61 1.46 1.95 1.49 
23 Regressor 2w PC 0.70 1.40 1.80 1.22 
23 Regressor 4w PC 3.66 18.02 4.81 13330.95 
23 Regressor 6w PC 3.92 12.05 5.69 2609.90 
23 Regressor 8w PC     
25 Regressor Pre-challenge 0.79 1.77 2.28 1.47 
25 Regressor 2w PC 0.66 1.26 1.90 1.25 
25 Regressor 4w PC 1.61 3.58 4.04 4.81 
25 Regressor 6w PC 1.33 6.35 2.63 27.95 
25 Regressor 8w PC 6.08 21.40 16.63 300.47 
26 Regressor Pre-challenge 0.78 1.36 2.20 1.48 
26 Regressor 2w PC 0.65 1.19 1.87 1.29 
26 Regressor 4w PC 0.91 6.28 2.43 2.27 
26 Regressor 6w PC 2.02 12.46 4.21 5.58 
26 Regressor 8w PC 5.07 11.54 7.60 15.60 
27 Regressor Pre-challenge 0.51 1.08 1.69 1.46 
27 Regressor 2w PC 0.48 1.21 1.72 1.48 
27 Regressor 4w PC     
27 Regressor 6w PC 3.49 25.01 9.11 54.53 
27 Regressor 8w PC 0.44 20.54 10.74 61.10 
28 Regressor Pre-challenge 0.61 1.24 1.93 1.48 
28 Regressor 2w PC 0.57 1.29 1.75 1.25 
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28 Regressor 4w PC 3.81 34.12 10.10 23.12 
28 Regressor 6w PC 1.19 28.73 14.93 33.62 
28 Regressor 8w PC     
29 Regressor Pre-challenge 0.55 1.18 1.87 1.53 
29 Regressor 2w PC 0.50 1.05 1.65 1.25 
29 Regressor 4w PC 0.77 5.67 2.12 1.55 
29 Regressor 6w PC 4.03 5.25 2.85 38.03 
29 Regressor 8w PC     
R01 Regressor Pre-challenge 1.16 1.68 2.96 1.42 
R01 Regressor 2w PC 0.82 1.42 2.44 1.44 
R01 Regressor 4w PC 1.90 7.29 4.18 1.83 
R01 Regressor 6w PC 2.55 11.12 3.61 9.52 
R01 Regressor 8w PC 1.68 3.70 3.32 10.76 
R02 Regressor Pre-challenge 7.38 10.48 11.70 1.46 
R02 Regressor 2w PC 2.39 3.41 5.07 1.40 
R02 Regressor 4w PC 1.87 4.89 3.78 3.65 
R02 Regressor 6w PC 1.85 4.06 2.86 4.98 
R02 Regressor 8w PC 1.30 3.29 2.76 5.73 
R03 Regressor Pre-challenge 0.94 2.10 2.29 1.47 
R03 Regressor 2w PC 0.72 1.73 2.00 1.37 
R03 Regressor 4w PC 0.67 1.83 1.89 1.43 
R03 Regressor 6w PC 1.01 1.95 2.02 2.34 
R03 Regressor 8w PC 1.00 2.01 2.15 2.03 
R04 Regressor Pre-challenge 47.17 30.66 68.25 1.45 
R04 Regressor 2w PC 11.75 10.98 18.95 1.42 
R04 Regressor 4w PC 5.62 5.40 9.53 1.44 
R04 Regressor 6w PC 5.80 7.58 6.59 2.05 
R04 Regressor 8w PC 3.84 9.30 4.48 3.02 
R05 Regressor Pre-challenge 10.80 9.20 23.12 1.40 
R05 Regressor 2w PC 5.00 4.69 8.91 1.35 
R05 Regressor 4w PC 2.12 2.88 4.33 1.41 
R05 Regressor 6w PC 1.88 3.11 3.79 1.60 
R05 Regressor 8w PC 3.46 4.21 6.11 1.82 
R07 Regressor Pre-challenge 0.51 1.17 1.64 1.46 
R07 Regressor 2w PC 0.48 1.12 1.60 1.37 
R07 Regressor 4w PC 0.93 5.09 2.30 4.86 
R07 Regressor 6w PC 1.78 8.42 4.01 5.98 
R07 Regressor 8w PC 2.22 9.95 4.34 8.54 
R11 Regressor Pre-challenge 3.76 3.91 7.29 1.43 
R11 Regressor 2w PC 2.71 3.25 5.02 1.38 
R11 Regressor 4w PC 2.65 5.40 3.85 7.30 
R11 Regressor 6w PC 2.49 4.79 3.99 210.46 
R11 Regressor 8w PC     
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R12 Regressor Pre-challenge 1.22 1.84 2.85 1.48 
R12 Regressor 2w PC 1.28 2.01 2.91 1.41 
R12 Regressor 4w PC 2.01 15.70 3.27 4.88 
R12 Regressor 6w PC     
R12 Regressor 8w PC     
R15 Regressor Pre-challenge 0.69 1.36 1.83 1.40 
R15 Regressor 2w PC 0.69 1.29 1.97 1.45 
R15 Regressor 4w PC 2.99 45.91 6.16 1.71 
R15 Regressor 6w PC 3.46 12.83 7.78 2.99 
R15 Regressor 8w PC 3.04 14.55 6.43 3.80 
 
 
 
Supplemental table A.2: VAPA ELISA results of naturally exposed foals at time points 1-4 
Foal Group Time Point Total IgG IgGa IgGb IgGt 
2 Progressor 1 90.5 135.7 237.7 10.1 
2 Progressor 2 43.3 60.5 243.2 5.2 
2 Progressor 3 67.8 70.3 131.3 3.2 
2 Progressor 4     
2 Progressor 5     
38 Progressor 1 176.2 370.1 838.9 1.8 
38 Progressor 2 74.4 87.7 107.5 1.8 
38 Progressor 3 96.5 80 213.4 2 
38 Progressor 4 143.9 75.3 181.6 1.7 
38 Progressor 5     
84 Progressor 1 51.2 32.3 83 5.4 
84 Progressor 2 44.2 45.6 89.3 3.6 
84 Progressor 3 79.5 154.8 106.2 7.3 
84 Progressor 4 76.1 82.4 181.6 6.5 
84 Progressor 5     
128 Progressor 1 55.5 67.3 107.2 6.6 
128 Progressor 2 108 209.6 438.9 4.9 
128 Progressor 3 116 71 205.2 3 
128 Progressor 4 36.7 27.9 69.1 2.6 
128 Progressor 5     
40 Progressor 1 147.8 105.5 545.5 1.8 
40 Progressor 2 118.1 50.2 340.5 3.5 
40 Progressor 3 24.8 24.9 80.4 2 
40 Progressor 4 45.4 39.8 82.8 2.1 
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Foal Group Time Point Total IgG IgGa IgGb IgGt 
40 Progressor 5     
28 Progressor 1 126.2 163.8 223.1 6.4 
28 Progressor 2 154.1 195.6 220.1 3.3 
28 Progressor 3 2.2 9.9 3.9 189.8 
28 Progressor 4     
28 Progressor 5     
32 Progressor 1 136.8 238.1 458.3 3.6 
32 Progressor 2 76.9 124.1 167.4 2.7 
32 Progressor 3 44.6 43.5 115.1 2.1 
32 Progressor 4 57.9 28.8 61.2 2.2 
32 Progressor 5     
75 Progressor 1 72.1 44 121.8 1.7 
75 Progressor 2 203.9 123.9 299.8 7.4 
75 Progressor 3 51.9 59.6 67.9 4.6 
75 Progressor 4 40.7 26.2 72.5 7.1 
75 Progressor 5     
87 Progressor 1 93.9 43.1 133.8 4.6 
87 Progressor 2 17.7 24.1 26.2 4.2 
87 Progressor 3     
87 Progressor 4     
87 Progressor 5     
66 Progressor 1 129.1 104.3 267.9 2 
66 Progressor 2 63.7 69.1 184 1.6 
66 Progressor 3     
66 Progressor 4     
66 Progressor 5     
78 Progressor 1 49.1 43.9 120.8 1.8 
78 Progressor 2 52.2 59.2 163.1 1.6 
78 Progressor 3     
78 Progressor 4     
78 Progressor 5     
3 Progressor 1 98.1 78.6 243.6 1.8 
3 Progressor 2 102.2 70.8 414.2 2.6 
3 Progressor 3 99.7 83.6 141.9 2.1 
3 Progressor 4     
3 Progressor 5     
7 Progressor 1 116.3 60.2 209.1 12.1 
7 Progressor 2 95.4 166.7 624.7 8.4 
7 Progressor 3 46.3 44.1 121.6 3.9 
7 Progressor 4 16 10.9 32.2 1.8 
7 Progressor 5 12.4 7.5 21.6 1.6 
37 Progressor 1 49.5 73 163.5 2.9 
37 Progressor 2 122.8 88 223.3 2.5 
37 Progressor 3 68.5 33.8 102.8 1.5 
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Foal Group Time Point Total IgG IgGa IgGb IgGt 
37 Progressor 4 23.2 10.3 32.3 1.3 
37 Progressor 5 4.8 3.5 8.7 1 
127 Regressor 1 31.5 76.4 142.7 5.9 
127 Regressor 2 79.3 18.5 64.4 3.6 
127 Regressor 3 28.9 21.2 46.4 2.6 
127 Regressor 4     
127 Regressor 5     
86 Regressor 1 169.4 74.9 248.6 8.8 
86 Regressor 2 400.3 69.7 171.6 10.9 
86 Regressor 3 87.5 56.1 107.6 8.5 
86 Regressor 4 46.1 23.5 44.7 4 
86 Regressor 5 57.7 36.7 109.5 4.3 
70 Regressor 1 47.6 46.4 95.5 2.08 
70 Regressor 2 27.8 29.7 83.4 1.4 
70 Regressor 3 20.1 37.1 41.5 1.4 
70 Regressor 4 24.7 24.7 22.7 1.2 
70 Regressor 5 5.3 14.6 17.5 1.1 
93 Regressor 1 90.6 129.5 158.9 9.5 
93 Regressor 2 29.7 26.9 81.5 2.9 
93 Regressor 3 26.6 18.6 36.8 1.9 
93 Regressor 4 16.6 11.4 29.6 1.8 
93 Regressor 5 8 6.2 21.9 1.4 
34 Regressor 1 55.8 68 149.4 3.1 
34 Regressor 2 54.8 26.6 70.2 2.2 
34 Regressor 3         
34 Regressor 4 4.6 3.3 6.5 3.7 
34 Regressor 5      
92 Regressor 1 0.6 1.1 1.7 1.3 
92 Regressor 2 0.6 1.3 1.8 1.2 
92 Regressor 3 11.6 34.1 23 47 
92 Regressor 4 21.9 47.7 44.7 1.7 
92 Regressor 5     
69 NRA 1 46.9 41.7 168.3 10.5 
69 NRA 2 54 64.1 165.1 4.1 
69 NRA 3 70 143.2 194 8.1 
69 NRA 4 78.2 29.7 81.6 6.5 
69 NRA 5         
102 NRA 1 114.6 67.8 167.7 9.2 
102 NRA 2 36.5 32.4 47 3.9 
102 NRA 3 18.5 12.9 34.5 5.9 
102 NRA 4 5.5 5.1 12.7 2.1 
102 NRA 5 6.6 3.7 17.6 2.1 
98 NRA 1 139.2 257.9 257.9 2.1 
98 NRA 2 19.9 168.7 168.7 1.4 
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Foal Group Time Point Total IgG IgGa IgGb IgGt 
98 NRA 3 24.6 27.8 27.8 1.6 
98 NRA 4 12.2 19.8 19.8 21.9 
98 NRA 5     
96 NRA 1 122.8 130.4 258.6 2 
96 NRA 2 101 31.1 100.8 1.4 
96 NRA 3 40.6 37.7 91.7 1.3 
96 NRA 4 23.3 12.3 28.8 1.3 
96 NRA 5 9 7.1 22.2 1 
72 NRA 1 203.6 140.1 245.7 2.19 
72 NRA 2 61.6 60.9 108.9 1.6 
72 NRA 3 32.6 14.5 38.7 1.2 
72 NRA 4 9.9 7.6 17.5 1.2 
72 NRA 5 7.9 6 14.8 1 
68 NRA 1 90.6 44.4 107.5 1.8 
68 NRA 2 77.2 54.2 156.1 1.4 
68 NRA 3 8.8 10.8 18.4 1.3 
68 NRA 4 10.2 9.6 23.9 0.8 
68 NRA 5 11.3 7.8 17.6 1.3 
9 NRA 1 114.6 76.1 153.2 7.5 
9 NRA 2 60.9 54.3 206.2 5.3 
9 NRA 3 52 27.5 67.2 4.6 
9 NRA 4 28.7 44.1 52.8 5.6 
9 NRA 5 17.8 18.9 24.8 2.9 
18 NRA 1 58.7 43.5 122.5 2.3 
18 NRA 2 55.7 36.9 73.5 1.9 
18 NRA 3 45.3 20.5 40.9 1.7 
18 NRA 4 9.2 12.9 22.5 1.3 
18 NRA 5 8.6 6.6 15.4 2.3 
20 NRA 1 91.6 93.4 231.8 2.6 
20 NRA 2 50 69 94.9 2.1 
20 NRA 3 14 14.7 24.3 1.6 
20 NRA 4 6.2 5.5 11 1.3 
20 NRA 5 5.3 5.1 8.7 1.2 
42 NRA 1 94.6 37.1 222.6 2.6 
42 NRA 2 62.5 35.7 99.1 2.2 
42 NRA 3 48.9 28.2 144 1.7 
42 NRA 4 41.5 27 45.7 2 
42 NRA 5 12 20.1 27.3 1.3 
47 NRA 1 131.7 57.4 187.2 2.4 
47 NRA 2 102.9 77.9 278 2.6 
47 NRA 3 45.2 23.2 49.8 1.6 
47 NRA 4     
47 NRA 5     
62 NRA 1 52.2 41.4 93.2 1.8 
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Foal Group Time Point Total IgG IgGa IgGb IgGt 
62 NRA 2 38.9 40.8 93.7 1.6 
62 NRA 3 14.4 20.1 34.4 1.4 
62 NRA 4 7 6.6 16.5 1 
62 NRA 5 8.5 9.3 14.6 3 
36 NRA 1 46.3 213.5 378.7 2 
36 NRA 2 237 101.8 587 9.5 
36 NRA 3 57.8 40.4 55.2 3.2 
36 NRA 4 46.9 19.4 88.1 2.1 
36 NRA 5     
41 NRA 1 186.4 59.8 286.3 1.6 
41 NRA 2 80.1 58.5 262.4 6 
41 NRA 3 64.8 68 238.4 3.2 
41 NRA 4 32.8 29.9 74 2.9 
41 NRA 5 43.7 18.3 61.9 2.2 
56 NRA 1 160.7 113.4 225.1 2.3 
56 NRA 2 94 80.2 176.2 6.2 
56 NRA 3 49.5 60.5 111.2 4.5 
56 NRA 4 103.5 78.4 100.5 7.3 
56 NRA 5 13.8 13.3 29.9 2.4 
57 NRA 1 190.1 112.3 214.5 2.3 
57 NRA 2 112.3 79.9 260.3 7.3 
57 NRA 3 39.6 19.7 170.1 4.5 
57 NRA 4 121.9 93 155.8 4 
57 NRA 5 76.1 51.5 89 0 
109 NRA 1 84.1 47.7 165.4 9.5 
109 NRA 2 32.9 21.3 93.7 4.1 
109 NRA 3 141.4 121.5 176.4 2.3 
109 NRA 4 76.2 50.3 118.9 2.1 
109 NRA 5 41.8 37.5 91.1 2.4 
117 NRA 1 217.2 90.6 453.9 7.7 
117 NRA 2 18.9 25 84.1 7.2 
117 NRA 3 156.2 60.5 188.7 2.2 
117 NRA 4 19.9 21.5 62.4 1.6 
117 NRA 5 17.8 9.6 22.6 8.5 
118 NRA 1 106.2 91.6 216.9 7.7 
118 NRA 2 59.3 43.1 130.1 6.6 
118 NRA 3 134.7 48.8 174.9 4.4 
118 NRA 4 72 84 158.1 3 
118 NRA 5 37.1 32.2 68.9 8.2 
120 NRA 1 145.1 110.6 280.5 8.1 
120 NRA 2 14.1 11.8 61.5 3.9 
120 NRA 3 105.6 102.5 167.6 2.2 
120 NRA 4 58.3 33.5 73.4 2.4 
120 NRA 5 22.1 20.9 45.3 2 
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Foal Group Time Point Total IgG IgGa IgGb IgGt 
125 NRA 1 78.4 55.6 187.2 6.2 
125 NRA 2 54.3 217.5 221.2 5.9 
125 NRA 3     
125 NRA 4     
125 NRA 5     
121 NRA 1 85 86.6 136.4 6.5 
121 NRA 2 94.7 72.4 245.1 6 
121 NRA 3 101 40 149.1 3.7 
121 NRA 4 24.8 15.1 53.4 1.5 
121 NRA 5     
131 NRA 1 200.8 54.7 138.4 8.2 
131 NRA 2 46 53.4 119.3 5.4 
131 NRA 3 118.6 94.7 220.9 3.4 
131 NRA 4 103.3 61.1 181.5 3 
131 NRA 5 46 29.9 81.3 2 
132 NRA 1 128.8 62.8 116.7 11.1 
132 NRA 2 73.2 63.7 158.9 8.5 
132 NRA 3 123.8 84.5 233.9 4.2 
132 NRA 4 148.9 104.6 304.9 3.2 
132 NRA 5 56.1 30.2 110.6 2 
129 NRA 1 259 59.2 130.2 9.6 
129 NRA 2 149.1 124.7 305 5 
129 NRA 3 64.2 69.5 259.7 3.2 
129 NRA 4 191.4 79.6 345.5 3 
129 NRA 5 27.3 25 72.7 3.4 
125 NRA 1 78.4 55.6 187.2 6.2 
125 NRA 2 54.3 217.5 221.2 5.9 
125 NRA 3     
125 NRA 4     
125 NRA 5     
65 NRA 1 68.2 67.6 142.4 10.4 
65 NRA 2 184.7 254 592.3 36.3 
65 NRA 3 66.3 79.6 233.5 11.4 
65 NRA 4 55.3 55.6 177.7 6.1 
65 NRA 5 74.8 33.9 104.2 3.9 
24 NRA 1 68.3 65.5 113.3 4.4 
24 NRA 2 237.8 227.9 332.6 8.6 
24 NRA 3 93.6 69.4 184.6 5.2 
24 NRA 4 49.2 31.9 94.1 2.5 
24 NRA 5 31.7 21.8 45.2 2.4 
30 NRA 1 34.3 187.3 528.9 2 
30 NRA 2 41.5 32.2 86.6 1.4 
30 NRA 3 210.4 101.3 210.5 3.9 
30 NRA 4 52.9 31.3 94.5 2.5 
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Foal Group Time Point Total IgG IgGa IgGb IgGt 
30 NRA 5 29.6 17 52.1 2 
8 NRA 1 85.9 68 214.8 7.1 
8 NRA 2 151.9 149.2 657.5 17.4 
8 NRA 3 134.8 82.7 169.9 6.9 
8 NRA 4 90.9 60.6 136.8 3.3 
8 NRA 5 31.2 22.5 80.6 2.7 
12 NRA 1 65.7 63.4 100.3 6.9 
12 NRA 2 54 48.3 105.3 4.6 
12 NRA 3 114.1 36.4 102.3 6.6 
12 NRA 4 84.4 76.2 196 4.1 
12 NRA 5 47.5 27.7 77.3 3 
22 NRA 1 68.8 82.6 255.5 2 
22 NRA 2 69.5 87.9 174.4 5.3 
22 NRA 3 185.4 78.3 266.4 4.3 
22 NRA 4 54.5 77.8 168.3 3.3 
22 NRA 5 50.8 21.7 93.2 2.2 
1 NRA 1 125.4 199.4 362.4 1.9 
1 NRA 2 130.1 163.5 593.6 2.7 
1 NRA 3 85.8 62.7 256.8 1.7 
1 NRA 4 11.8 6.5 15.7 1.2 
1 NRA 5         
5 NRA 1 59.9 53.4 182.3 1.8 
5 NRA 2 157.1 181.8 347.3 3 
5 NRA 3 9.4 8.6 16 3.4 
5 NRA 4         
5 NRA 5         
19 NRA 1 120.6 88.4 328.8 3 
19 NRA 2 109.9 171.7 190.8 2.7 
19 NRA 3 66.3 50.8 126.9 1.7 
19 NRA 4 19.3 16.7 29.8 1.4 
19 NRA 5     
25 NRA 1 92.2 159 405.6 3.3 
25 NRA 2 193.1 217.8 665.6 3.3 
25 NRA 3 83.8 49.3 93.1 1.8 
25 NRA 4 25 14.8 28.9 1.4 
25 NRA 5         
31 NRA 1 95.7 69.4 206.3 2.6 
31 NRA 2 110.5 208 214.1 2.6 
31 NRA 3 92.8 43.1 80 1.7 
31 NRA 4         
31 NRA 5         
39 NRA 1 170.4 59.6 435.1 2.8 
39 NRA 2 70 69.6 242.4 2.5 
39 NRA 3 19.8 34 32.6 1.6 
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Foal Group Time Point Total IgG IgGa IgGb IgGt 
39 NRA 5         
44 NRA 1 55.2 65 398.3 2.6 
44 NRA 2         
44 NRA 3 20.4 28.4 37 19.5 
44 NRA 4 11.1 12.7 18.1 15.6 
44 NRA 5         
58 NRA 1 93.4 68.2 154.6 2.1 
58 NRA 2 73.3 80.2 187.2 5.4 
58 NRA 3 45.1 31 60.1 4 
58 NRA 4 12.6 9.2 26.6 2 
58 NRA 5         
76 NRA 1 84.2 59.2 177.9 2 
76 NRA 2 115 119.4 235.1 8.3 
76 NRA 3 105 471.9 64.1 3.2 
76 NRA 4         
76 NRA 5         
103 NRA 1 53.6 49.7 147.7 1.9 
103 NRA 2 81.2 101.6 188.8 15.4 
103 NRA 3         
103 NRA 4         
103 NRA 5         
107 NRA 1 115.9 104.6 234.6 2.1 
107 NRA 2 105.5 153.6 278.8 1.8 
107 NRA 3     
107 NRA 4     
107 NRA 5     
114 NRA 1 70.5 74.9 152.5 9.3 
114 NRA 2 23.1 39.7 92.6 2.3 
114 NRA 3     
114 NRA 4     
114 NRA 5     
115 NRA 1 66.2 56.7 131 1.8 
115 NRA 2 101.2 46.8 102.5 2.2 
115 NRA 3     
115 NRA 4     
115 NRA 5     
119 NRA 1 154.6 99.8 268.6 9.7 
119 NRA 2 302.1 99.9 230.3 8.5 
119 NRA 3     
119 NRA 4     
119 NRA 5     
123 NRA 1         
123 NRA 2 106.3 60.1 164.8 1.2 
123 NRA 3         
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Foal Group Time Point Total IgG IgGa IgGb IgGt 
123 NRA 5         
126 NRA 1         
126 NRA 2 48.2 59.1 130.6 3 
126 NRA 3     
126 NRA 4     
126 NRA 5     
130 NRA 1         
130 NRA 2 72.5 109.9 219.6 1.8 
130 NRA 3         
130 NRA 4     
130 NRA 5     
10 NRA 1 83.2 69 186.8 9.3 
10 NRA 2 49.5 40.2 124.2 4.3 
10 NRA 3 46.3 26.7 43.7 2.3 
10 NRA 4 12 6.8 18.3 1.7 
10 NRA 5         
43 NRA 1 37.1 33 118.4 2.3 
43 NRA 2         
43 NRA 3 16.8 10.8 29.1 0.9 
43 NRA 4 4.1 3.3 7 1.4 
43 NRA 5     
46 NRA 1 66.2 63.9 214 5.3 
46 NRA 2 40.8 16.9 46.1 2.4 
46 NRA 3 2.7 2.7 5 1.5 
46 NRA 4         
46 NRA 5     
48 NRA 1 53.5 34.5 109.7 2.2 
48 NRA 2 44.4 33.9 82.2 2.1 
48 NRA 3 9.4 4.4 9.3 1.4 
48 NRA 4     
48 NRA 5     
50 NRA 1 66.6 51.3 157.5 6.1 
50 NRA 2 66.3 30.6 99 2.4 
50 NRA 3 24.3 28.2 27.3 12.2 
50 NRA 4     
50 NRA 5     
51 NRA 1 0.8 1.3 2.4 1.2 
51 NRA 2 0.8 1.4 1.9 1.5 
51 NRA 3     
51 NRA 4     
51 NRA 5     
82 NRA 1 39.7 50.3 108.8 2.7 
82 NRA 2 39.9 31.5 85.2 2.2 
82 NRA 3 19.7 34.3 36.1 3.1 
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Foal Group Time Point Total IgG IgGa IgGb IgGt 
82 NRA 5     
85 NRA 1 70.3 38 89.5 2 
85 NRA 2 12.6 18.4 25.6 1.5 
85 NRA 3 10.1 5.8 15.7 1.4 
85 NRA 4 3.4 3.4 8.8 1 
85 NRA 5     
104 NRA 1 102.7 84 154.9 1.8 
104 NRA 2 35.2 30.1 51 1.4 
104 NRA 3 22 30.6 73.1 1.4 
104 NRA 4 6.8 6 15.3 1.1 
104 NRA 5         
11 NRA 1 76.8 47.6 124.4 1.7 
11 NRA 2 89.1 122.2 426.6 2.4 
11 NRA 3 109.7 62.8 262.4 1.8 
11 NRA 4         
11 NRA 5         
55 NRA 1 120.9 76.7 282.9 1.7 
55 NRA 2 109.7 84.9 206.5 6.4 
55 NRA 3 91 46.3 99.4 2.9 
55 NRA 4 17 16.4 35.1 2.3 
55 NRA 5         
90 NRA 1 113 56.3 157.8 1.8 
90 NRA 2 83.8 99 182 2 
90 NRA 3 13.9 33.8 34.4 36.7 
90 NRA 4         
90 NRA 5         
108 NRA 1 113.5 83.4 220.1 7.5 
108 NRA 2 110.8 153.6 337 3.6 
108 NRA 3 57.5 29.1 79.8 2.2 
108 NRA 4         
108 NRA 5         
110 NRA 1         
110 NRA 2 25.2 63.6 127.5 2.3 
110 NRA 3 40.3 57.3 157.3 2.5 
110 NRA 4 20.5 18 68.5 1.3 
110 NRA 5         
13 NRA 1 94.4 156.3 365.2 3 
13 NRA 2 109.8 76.7 292.5 2 
13 NRA 3 2.7 2.9 5.3 1.4 
13 NRA 4 5.4 6.6 7.4 14.5 
13 NRA 5         
27 NRA 1 1.3 1.8 3.5 1.3 
27 NRA 2 1.5 1.8 3.2 1.5 
27 NRA 3 5.2 14.1 9.3 66.6 
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Foal Group Time Point Total IgG IgGa IgGb IgGt 
27 NRA 5         
29 NRA 1 175.1 129.9 262.5 1.4 
29 NRA 2 53.4 43 63.7 1.5 
29 NRA 3         
29 NRA 4     
29 NRA 5     
59 NRA 1 124.4 83.6 208.3 2.3 
59 NRA 2 66.1 35.5 97.2 1.6 
59 NRA 3 16 15.1 31.8 2 
59 NRA 4 11.7 11 16.5 2.2 
59 NRA 5 5 3.7 7.8 2.2 
60 NRA 1 0.9 1.6 2.5 1.4 
60 NRA 2 0.9 1.7 2.1 1.4 
60 NRA 3 1.3 3.8 2.2 7.6 
60 NRA 4 2.2 6.4 4.2 9.1 
60 NRA 5     
80 NRA 1 47.1 25.4 64.1 4.1 
80 NRA 2 19 37.7 94.7 2.4 
80 NRA 3         
80 NRA 4         
80 NRA 5         
89 NRA 1 155.3 126.1 473.4 2.9 
89 NRA 2 93.1 38.9 45.4 1.9 
89 NRA 3 37.7 18.4 23.2 2 
89 NRA 4         
89 NRA 5         
94 NRA 1 78.8 51.6 103.7 8 
94 NRA 2 121.5 114.1 201 6.7 
94 NRA 3 35.1 20.9 50.7 2.5 
94 NRA 4         
94 NRA 5     
95 NRA 1 105.4 100.9 170.6 3 
95 NRA 2 70.5 45.4 174.8 2.6 
95 NRA 3 70.1 60.9 179.1 2 
95 NRA 4     
95 NRA 5     
6 NRA 1 38.3 43 209.5 1.9 
6 NRA 2 53.8 65.9 377 2.4 
6 NRA 3 101.9 49.9 138.1 1.6 
6 NRA 4 11.8 7.2 23.1 1.3 
6 NRA 5     
17 NRA 1 160.9 60.7 164.4 1.8 
17 NRA 2 104 73.9 225.8 6 
17 NRA 3 100.8 52.1 103.7 2.3 
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Foal Group Time Point Total IgG IgGa IgGb IgGt 
17 NRA 5     
35 NRA 1 43.5 107 207.1 2.6 
35 NRA 2 154.3 72.9 185.1 2.5 
35 NRA 3 28.3 54.2 76.5 1.6 
35 NRA 4 33.9 16.8 47.7 1.4 
35 NRA 5         
111 NRA 1 76.6 72.8 151.4 10.1 
111 NRA 2 50.4 55.9 117.9 3.2 
111 NRA 3 46.3 37 86.1 2.4 
111 NRA 4 16.9 15.9 43.3 2.2 
111 NRA 5     
112 NRA 1 84.7 52.5 198.3 8 
112 NRA 2 26.9 35.4 119.8 3.1 
112 NRA 3     
112 NRA 4     
112 NRA 5     
134 NRA 1 21.3 18 45.6 1.3 
134 NRA 2     
134 NRA 3     
134 NRA 4     
134 NRA 5     
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Clinical Mentor: Jay Addison, DVM 
 
Patricia Brossi, DVM, MS, PhD - Sao Paulo, Brazil                                             
Equine Veterinarian  
2007 – 2008 
      
Sao Paulo Jockey Club Equine Hospital, Sao Paulo, SP (Brazil)                    
Intern in Equine Medicine and Surgery 
2006 – 2007 
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RESEARCH GRANTS 
 
Grayson-Jockey Club Research Foundation, Inc.  
Cesar, F.B., Horohov, D.W. Do IgGt antibodies identify foals at risk for rhodococcal pneumonia? 
February, 2016. $62,407 
 
Animal Health and Disease, College of Veterinary Medicine, Auburn University  
Cesar, F.B., Stewart, A., Boothe, D.M., Ravis, W.A., Duran, S.H., Wooldridge, A.A., Wilborn, R.R. 
Disposition of levetiracetam in healthy adult horses. 2012-2014. $30,000. 
 
National Council of Technological and Scientific Development, College of Veterinary Medicine, University 
of Brasilia  
Cesar, F.B., Selmi, A.L. Comparison between the analgesic efficacy of carprofen, vedaprofen and 
ketoprofen for post-operatory pain control in female dogs submitted to ovariosalpingohysterectomy. 
2001-2002 
 
 
PER REVIEWED PUBLICATIONS 
 
Cesar, F.B., Stewart, A., Boothe, D.M., Ravis, W.A., Duran, S.H., Wooldridge, A.A. and Wilborn, R.R. 
(2017) Disposition of levetiracetam in healthy adult horses. Journal of Veterinary Pharmacology and 
Therapeutics, May 15, 2017. DOI: 10.1111/jvp.12417. 
 
Cesar, F.B., Paudel, S., Horohov, D. (2016) The use of IgGt as a diagnostic tool in foals with naturally 
acquired Rhodococcus equi pneumonia. In: 2016 CRWAD proceedings.  
 
Adams, A.A., Siard, M.H., Reedy, S.E., Braker, D., Elzinga, S., Sanz, M., Cesar, F.B., Lawson, C., Tucker, 
C., Mulholland, M., Horohov, D., Urschel, C., Ireland, J. Evaluating seasonal influences on hormone 
responses to a diagnostic test (thyrotropin-releasing hormone stimulation) advocated for early diagnosis of 
pituitary pars intermedia dysfunction. In: 2016 AAEP proceedings 62; 504-505. 
  
Cesar, F.B., Joiner, K.S., Albanese, V.A., Groover, E.S., Waguespack, R.W. (2016) Osteoblastic 
osteosarcoma of the paranasal sinuses of an one-year-old American Quarter Horse colt. Journal of the 
American Veterinary Medical Association - Pathology in Practice, 248(7). 
 
Cesar, F.B., Stewart, A., Boothe, D.M., Ravis, W.A., Duran, S.H., Wooldridge, A.A. and Wilborn, R.R. 
(2013) Disposition of levetiracetam in healthy adult horses. Journal of Veterinary Internal Medicine. In: 
2013 ACVIM Forum Research Abstracts Program 27 (3); 604-756. 
 
Mastrorilli, C., Cesar, F.B., Joiner, K.S, Wooldridge, A.A., Christopherson, P.W. Disseminated lymphoma 
with large granular lymphocyte morphology diagnosed in a horse via abdominal fluid and transtracheal wash 
cytology. Veterinary Clinical Pathology, May 4, 2015. DOI: 10.1111/vcp.12262. 
 
Schumacher, J., DeGraves, F., Cesar, F., Duran, S. (2013) Efficacy of ketamine hydrochloride administered 
as a basilar sesamoid nerve block in alleviating foot pain caused by natural disease. Equine Veterinary 
Journal, 46(5), 639-641. 
 
Barba, M., Barret, L., Cesar, F.B., Caldwell, F., Schumacher, J. (2013) Management of enterocutaneous 
fistula associated with an umbilical hernia in a two-year-old horse. Veterinary Records Case Reports, online 
publication November, 2013. DOI: 10.1136/vetreccr-2013-000014. 
 
Cesar, F.B., Johnson, C.R. and Pantaleon, L.G. (2010) Suspected idiopathic intestinal lymphangiectasia in 
two foals with chylous peritoneal effusion. Equine Veterinary Education 22 (4); 172-178.   
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HONOURABLE MENTIONS 
 
American College of Veterinary Internal Medicine Resident Research Award, June 2013 
Cesar, F.B., Stewart, A., Boothe, D.M., Ravis, W.A., Duran, S.H., Wooldridge, A.A. and Wilborn, 
R.R. Disposition of levetiracetam in healthy adult horses.  
 
Auburn University Certificate of Achievement for Academic Excellence as Outstanding Graduate Student, 
July 2013 
 
Phi Zeta Honor Society induction, October 2013 
 
III International Symposium of the Athlete Horse Best Published Paper, April 2007          
Cesar, F.B. and Laguna-Legorreta, G.G. (2007) Retrospective study of the fatal and non-fatal 
catastrophic injuries during Thoroughbred races at Soao Paulo’s Jockey Club racetrack between 
l996 and 2006. In: Proceedings III International Symposium of the Athlete Horse. Belo Horizonte, 
MG. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
